[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 6968
1. Reiffel AJ, Reiffel JA: QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT. J Atr Fibrillation; 2009 Feb-Mar;1(5):113

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT.
  • <b>Background:</b> Ectopic beats are frequently associated with morphologic repolarization alterations of ensuing sinus beats.
  • In one patient who developed long QT and torsades de pointes upon exposure to a class III antiarrhythmic drug, and was later genotyped as being a carrier for long QT syndrome (LQTS) type 1, review of a pre-drug Holter monitor study revealed marked QT prolongation of post-ectopic sinus beats.
  • Prolongation beyond the upper limit of this range might then raise suspicion of possible LQTS and alter the antiarrhythmic drug selection process for the suppression of atrial fibrillation or other arrhythmias.
  • <b>Methods:</b> Accordingly, we assessed the presence/degree of repolarization prolongation following premature ectopic impulses in 166 subjects with normal conduction intervals and normal repolarization on their resting 12-lead ECG, 75 of whom had no known associated cardiovascular disorder of any kind.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2002 Jun 5;39(11):1820-6 [12039498.001]
  • [Cites] Jpn Circ J. 1998 Mar;62(3):215-8 [9583450.001]
  • [Cites] Am J Cardiol. 1997 Mar 15;79(6):816-9 [9070571.001]
  • [Cites] Heart Rhythm. 2008 Jan;5(1):11-8 [18180017.001]
  • [Cites] J Electrocardiol. 2004 Jul;37(3):181-9 [15286931.001]
  • [Cites] JAMA. 2003 Apr 23-30;289(16):2041-4 [12709446.001]
  • [Cites] Heart Rhythm. 2007 May;4(5):603-7 [17467628.001]
  • (PMID = 28496607.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Wang L, He X, Wilkie CA: The Utility of Nanocomposites in Fire Retardancy. Materials (Basel); 2010 Sep 03;3(9):4580-4606

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nanocomposites have been shown to significantly reduce the peak heat release rate, as measured by cone calorimetry, for many polymers but they typically have no effect on the oxygen index or the UL-94 classification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Bioanal Chem. 2008 Mar;390(6):1455-61 [17952415.001]
  • [Cites] J Phys Chem B. 2007 Nov 8;111(44):12685-92 [17944513.001]
  • [Cites] J Nanosci Nanotechnol. 2005 Oct;5(10):1574-92 [16245517.001]
  • [Cites] Phys Rev Lett. 2005 Aug 19;95(8):088303 [16196908.001]
  • [Cites] Chem Rev. 2008 Sep;108(9):3893-957 [18720998.001]
  • [Cites] J Nanosci Nanotechnol. 2008 Apr;8(4):1597-615 [18572560.001]
  • (PMID = 28883342.001).
  • [ISSN] 1996-1944
  • [Journal-full-title] Materials (Basel, Switzerland)
  • [ISO-abbreviation] Materials (Basel)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; clays / fire retardancy / nanocomposites
  •  go-up   go-down


3. Vieira SC, França JC, Fé JA, Santos LG, Almeida NM: [Benign metastasizing uterine leiomyoma: case reports]. Rev Bras Ginecol Obstet; 2009 Aug;31(8):411-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign metastasizing uterine leiomyoma: case reports].
  • [Transliterated title] Leiomioma uterino metastatizante benigno: relato de dois casos.
  • Benign metastasizing leiomyomatosis (BML) is a rare disease in which the lung is the most affected extra-uterine organ.
  • The BML histology is compatible with benignity and similar to that found in the myometrial leiomyoma.
  • A history of surgically treated uterine myomatosis is reported by most of the patients with metastatic disease.
  • We report the cases of two patients with uterine metastasizing leiomyomatosis.
  • In the first case, a 55-year-old patient presented lung nodes over 20 years after being submitted to hysterectomy due to uterine leiomyoma.
  • The histological and immunohistochemical studies from the lung node revealed that it was an implant of benign leiomyoma.
  • The second patient, a 65-years-old woman, presented lung and retroperitoneal nodes 20 years after being submitted to a hysterectomy due to uterine leiomyoma.
  • [MeSH-major] Leiomyoma / pathology. Lung Neoplasms / secondary. Retroperitoneal Neoplasms / secondary. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838590.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Dragomir AD, Schroeder JC, Connolly A, Kupper LL, Cousins DS, Olshan AF, Baird DD: Uterine leiomyomata associated with self-reported stress urinary incontinence. J Womens Health (Larchmt); 2010 Feb;19(2):245-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine leiomyomata associated with self-reported stress urinary incontinence.
  • AIMS: To investigate the association between the presence and characteristics of uterine leiomyomata (UL) and self-reported stress urinary incontinence (SUI).
  • METHODS: The study included 836 premenopausal participants (474 African American and 362 Caucasian) in the National Institute of Environmental Health Sciences (NIEHS) Uterine Fibroid Study.
  • UL were characterized at baseline with ultrasound screening, and SUI was assessed at follow-up (after 4 years, on average).
  • Linear risk models were used to estimate adjusted prevalence differences (aPD) and 95% confidence intervals (CI), controlling for age, ethnicity, body mass index (BMI), and number of deliveries.
  • RESULTS: Compared with women without UL, SUI prevalence was higher among women with any UL (aPD = 7.4%, 95% CI 0.4-14.3) and women with UL 2-4 cm (aPD = 9.6%, 95% CI 1.3-17.9).
  • Marginally significant results were found for the presence of UL > or =4 cm and anterior UL > or =2 cm.
  • CONCLUSIONS: The observed 7% increase in prevalence of this common condition for women with UL is of clinical importance.
  • Further research is needed before concluding that treatment for larger UL might enhance SUI treatment in some women.

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 2000 Oct;108 Suppl 5:835-9 [11035991.001]
  • [Cites] Int J Obes (Lond). 2008 Sep;32(9):1415-22 [18626483.001]
  • [Cites] J Am Geriatr Soc. 2001 Jun;49(6):829-30 [11454125.001]
  • [Cites] Obstet Gynecol. 2001 Dec;98(6):1004-10 [11755545.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jul;187(1):116-26 [12114899.001]
  • [Cites] N Engl J Med. 2002 Oct 24;347(17):1318-25 [12397189.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jan;188(1):100-7 [12548202.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):900-7 [12621134.001]
  • [Cites] Obstet Gynecol. 2003 Mar;101(3):431-7 [12636944.001]
  • [Cites] Urology. 2004 Mar;63(3):461-5 [15028438.001]
  • [Cites] J Obstet Gynaecol. 2004 Jun;24(4):420-5 [15203584.001]
  • [Cites] Obstet Gynecol. 2004 Aug;104(2):301-7 [15292003.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jul;86 Suppl 1:S6-16 [15302563.001]
  • [Cites] Obstet Gynecol. 2004 Sep;104(3):607-20 [15339776.001]
  • [Cites] Am J Obstet Gynecol. 2004 Aug;191(2):463-9 [15343222.001]
  • [Cites] Eur Urol. 1997;32 Suppl 2:3-12 [9248806.001]
  • [Cites] Am J Epidemiol. 2005 Aug 1;162(3):199-200 [15987728.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Jul-Aug;16(4):257-62 [16220584.001]
  • [Cites] Scand J Prim Health Care. 2005 Dec;23(4):203-8 [16272067.001]
  • [Cites] Am J Obstet Gynecol. 2005 Dec;193(6):2149-53 [16325632.001]
  • [Cites] J Urol. 2006 Jan;175(1):259-64 [16406923.001]
  • [Cites] Am J Epidemiol. 2007 Feb 1;165(3):309-18 [17132698.001]
  • [Cites] Clin Obstet Gynecol. 2001 Jun;44(2):364-71 [11344999.001]
  • (PMID = 20095907.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NICHD NIH HHS / HD / R24 HD050924; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2834441
  •  go-up   go-down


5. Munro IC: Setting tolerable upper intake levels for nutrients. J Nutr; 2006 Feb;136(2):490S-492S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Setting tolerable upper intake levels for nutrients.
  • Because no one had previously developed a comprehensive approach to the risk assessment of nutrients, the FNB Subcommittee on Upper Reference Levels of Nutrients first looked at various options that could be used to accomplish this task.
  • During initial meetings, the committee considered a variety of options for setting tolerable upper intake levels and settled on the risk assessment approach described in this paper.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424133.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Wise LA, Palmer JR, Stewart EA, Rosenberg L: Polycystic ovary syndrome and risk of uterine leiomyomata. Fertil Steril; 2007 May;87(5):1108-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycystic ovary syndrome and risk of uterine leiomyomata.
  • OBJECTIVE: To examine the association between polycystic ovary syndrome (PCOS) and the risk of uterine leiomyomata (UL).
  • PATIENT(S): Premenopausal women with no history of UL at the start of follow-up (N = 23,571).
  • MAIN OUTCOME MEASURE: Incidence of UL among those with and without self-reported, physician-diagnosed PCOS over a 6-year period of follow-up (1997-2003).
  • Medical-record validation in a random subset of UL cases confirmed 96% of diagnoses.
  • RESULT(S): During 114,373 person-years of follow-up, 3,631 new cases of UL confirmed by ultrasound (N = 2,926) or hysterectomy (N = 705) were reported.
  • After adjustment for potential confounders, the incidence of UL was 65% higher among women with PCOS than women without PCOS (incidence rate ratio, 1.65; 95% confidence interval, 1.21-2.24).
  • The incidence rate ratios remained constant with increasing time after the diagnosis of PCOS.
  • Results were similar when analyses were confined to women reporting a recent Papanicolaou smear, a proxy for a pelvic examination.
  • CONCLUSION(S): The present study suggests a positive association between PCOS and UL in African-American women.

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2001 Nov-Dec;8(6):319-26 [11750866.001]
  • [Cites] Eur J Endocrinol. 2001 Dec;145(6):749-55 [11720900.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):409-15 [11904599.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1723-7 [12365955.001]
  • [Cites] Obstet Gynecol Surv. 2002 Nov;57(11):755-67 [12447098.001]
  • [Cites] Reprod Biomed Online. 2003 Jul-Aug;7(1):59-64 [12930575.001]
  • [Cites] Obstet Gynecol. 2004 Jan;103(1):181-93 [14704263.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):113-23 [14718211.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9 [15181052.001]
  • [Cites] Endocr Rev. 1987 May;8(2):132-41 [3301317.001]
  • [Cites] Am J Public Health. 1989 Mar;79(3):340-9 [2916724.001]
  • [Cites] Horm Metab Res. 1989 Jul;21(7):391-7 [2777199.001]
  • [Cites] Gynecol Obstet Invest. 1990;29(1):47-50 [2190879.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6689-95 [2208134.001]
  • [Cites] Fertil Steril. 1991 May;55(5):900-5 [1902420.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):811-7 [1909705.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1991 Sep 13;41(2):143-50 [1936493.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604 [1336918.001]
  • [Cites] Ann Med. 1993 Aug;25(4):307-8 [8217093.001]
  • [Cites] Hum Reprod. 1993 Nov;8(11):1796-806 [7507128.001]
  • [Cites] Metabolism. 1994 Jun;43(6):706-13 [8201958.001]
  • [Cites] J Am Med Womens Assoc. 1995 Mar-Apr;50(2):56-8 [7722208.001]
  • [Cites] Fertil Steril. 1997 Mar;67(3):452-8 [9091329.001]
  • [Cites] Vital Health Stat 23. 1997 May;(19):1-114 [9201902.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2248-56 [9215302.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3078-82 [9745406.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 2):S89-S93 [9855614.001]
  • [Cites] Eur Cytokine Netw. 2004 Oct-Dec;15(4):359-63 [15627646.001]
  • [Cites] Gynecol Endocrinol. 2004 Sep;19(3):125-33 [15697073.001]
  • [Cites] Obstet Gynecol. 2005 Mar;105(3):563-8 [15738025.001]
  • [Cites] Am J Epidemiol. 2005 Apr 1;161(7):628-38 [15781952.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1223-36 [15788499.001]
  • [Cites] Epidemiology. 2005 May;16(3):346-54 [15824551.001]
  • [Cites] Gynecol Endocrinol. 2005 Apr;20(4):200-8 [16019362.001]
  • [Cites] Hum Reprod. 2005 Sep;20(9):2402-8 [15932911.001]
  • [Cites] J Soc Gynecol Investig. 2006 Feb;13(2):130-5 [16443507.001]
  • [Cites] Hum Reprod. 2004 Jan;19(1):41-7 [14688154.001]
  • [Cites] Hum Reprod. 2000 Jan;15(1):24-8 [10611183.001]
  • [Cites] Am J Epidemiol. 2001 Jan 1;153(1):11-9 [11159140.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):293-8 [11214143.001]
  • [Cites] Reproduction. 2001 Jun;121(6):835-42 [11373169.001]
  • [Cites] J Endocrinol. 2002 Jan;172(1):83-93 [11786376.001]
  • (PMID = 17241625.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA058420; United States / NCI NIH HHS / CA / CA58420
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS19331; NLM/ PMC1876794
  •  go-up   go-down


7. Auguściak-Duma A, Sieroń AL: [Molecular characteristics of leiomyoma uteri based on selected compounds of the extracellular matrix]. Postepy Hig Med Dosw (Online); 2008 Jan 14;62:148-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular characteristics of leiomyoma uteri based on selected compounds of the extracellular matrix].
  • [Transliterated title] Molekularna charakterystyka guzów leiomyoma uteri na przykładzie wybranych składników macierzy pozakomórkowej.
  • Leiomyoma is a monoclonal benign tumor.
  • It is often located in the muscle layer of the uterus in women of reproductive age.
  • Growth factors and cytokines may also participate in the formation of leiomyomas.
  • The modulation of mitotic activity and abnormal extracellular matrix production are key elements of tumor growth.
  • Another aspect is induction of the development of muscle and neural tissue by activation of GDF8 and GDF11 as well as the regulation of growth and cell proliferation by releasing TGF-beta1 and -beta3 from latent complexes.
  • The detectable karyotype anomalies in tumor cells constitute just 40%.
  • Therefore in this review the possible roles of extracellular matrix compounds and regulatory factors in the pathology of leiomyoma are discussed.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18464678.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / Extracellular Matrix Proteins; 0 / Glycoproteins; 0 / PCOLCE protein, human; 0 / Transforming Growth Factor beta1; 0 / Transforming Growth Factor beta3; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.19 / BMP1 protein, human; EC 3.4.24.19 / Bone Morphogenetic Protein 1
  • [Number-of-references] 136
  •  go-up   go-down


8. Dairy foods reduce risk of fibroids in black women. Nurs Stand; 2010 Feb 17;24(24):16-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dairy foods reduce risk of fibroids in black women.
  • : Black women are at a reduced risk of uterine leiomyomata if they eat dairy foods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28029984.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. El-Bassiouni EA, Helmy MH, El-Zoghby SM, Kamel EN, Hosny RM: Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br J Biomed Sci; 2007 Jan;64(3):109-116
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients.
  • The aim of the present study is to evaluate the possible relationship between the circulating levels of the modified derivatives of low-density lipoprotein (LDL) and the development of angiopathy in type 2 diabetic patients with CAD.
  • The study has shown alteration in the lipid profile in diabetic groups, where the oxidised LDL (ox-LDL) levels were significantly higher than in control subjects.
  • Diabetics with CAD had higher levels of ox-LDL than did patients without CAD.
  • The intima/media thickness (IMT) of the carotid artery was within clinically accepted normal values if the ox-LDL level was below 100-110 u/L.
  • It seems that the level of ox-LDL should be kept below an upper limit of the 100-110 u/L range in order to avoid the serious atherosclerotic effects of this factor.
  • The results demonstrate that plasma levels of ox-LDL correlate with the extent of coronary artery disease in type 2 diabetic patients and suggest that elevated levels of ox-LDL, can serve as an independent and significant predictor for future cardiac events in type 2 diabetic patients with CAD.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28705143.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Coronary artery disease / Diabetes mellitus / Lipoprotein / low density
  •  go-up   go-down


10. Beden U, Ozarslan Y, Ozturk HE, Sonmez B, Erkan D, Oge I: Exophthalmometry values of Turkish adult population and the effect of age, sex, refractive status, and Hertel base values on Hertel readings. Eur J Ophthalmol; 2008 Mar-Apr;18(2):165-171

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Median Hertel reading was 13 mm, and 95% of the population had an upper limit of 17 mm for both eyes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221633.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Nicoletti S, Castoro V, Iacobellis M, Loizzo N, Monopoli L: [Upper limb work-related musculoskeletal disorders (UL-WMSDs) in a large factory of the upholstered furniture industry: risk management]. Med Lav; 2008 Jul-Aug;99(4):297-313
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upper limb work-related musculoskeletal disorders (UL-WMSDs) in a large factory of the upholstered furniture industry: risk management].
  • [Transliterated title] La gestione del rischio di UL-WMSDs in una grande azienda del mobile imbottito.
  • BACKGROUND: The industrial production of upholstered furniture exposes workers to significant risk of occupational disorders due to ergonomics-related problems, such as repetitive strain and movements of the upper limb, manual load lifting, prolonged static postures.
  • At the same time the incidence rate of work-related upper limb musculoskeletal disorders (UL-WMSDs) in the population of workers (which had increased in the meantime from 2500 to 3500 employees) reached nearly 5% in 2001, with peaks of 8-9% in the work tasks with higher exposure.
  • [MeSH-major] Arm. Cumulative Trauma Disorders / epidemiology. Human Engineering / methods. Interior Design and Furnishings. Musculoskeletal Diseases / epidemiology. Occupational Diseases / epidemiology

  • MedlinePlus Health Information. consumer health - Ergonomics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717527.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Pagni F, Bono F, Di Bella C, Galbiati E, Faravelli A: [Myeloid sarcoma in uterine leiomyoma]. Pathologica; 2008 Feb;100(1):21-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myeloid sarcoma in uterine leiomyoma].
  • [Transliterated title] Sarcoma mieloide in leiomioma del miometrio.
  • Histological analysis showed a classic leiomyoma infiltrated by a second monomorphic, highly undifferentiated neoplasia.
  • A diagnosis of myeloid sarcoma in myometrial leiomyoma was made.
  • Forty days after diagnosis the patient died for complications related to immunodeficiency caused by therapy.
  • Especially when a common antibody panel reveals negativity for epithelial, mesenchymal and lymphoid markers, this case underlines the importance of considering myeloid sarcoma in differential diagnosis of undifferentiated tumours arising in an extramedullary site in order to avoid errors and permit optimal therapeutic management.
  • [MeSH-major] Leiomyoma / pathology. Sarcoma, Myeloid / pathology. Uterine Neoplasms / pathology


13. Vercaemst C, de Jongh PE, Meeldijk JD, Goderis B, Verpoort F, Van Der Voort P: Ethenylene-bridged periodic mesoporous organosilicas with ultra-large mesopores. Chem Commun (Camb); 2009 Jul 21;(27):4052-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethenylene-bridged periodic mesoporous organosilicas with ultra-large mesopores.
  • E-configured ethenylene-bridged periodic mesoporous organosilicas with ultra-large mesopores and unprecedented pore volumes have been developed for the first time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19568630.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Hodge JC, Morton CC: Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet; 2007 Apr 15;16 Spec No 1:R7-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity among uterine leiomyomata: insights into malignant progression.
  • Uterine leiomyomata (UL), also known as fibroids, are the most common pelvic tumors in women of reproductive age and are the primary indication for hysterectomy in the USA.
  • In fact, approximately 40% of UL have non-random, tumor-specific chromosome abnormalities which have allowed classification into well-defined subgroups (deletion of portions of 7q, trisomy 12 or rearrangements of 12q15, 6p21 or 10q22) as well as identification of candidate genes for UL predisposition.
  • Although benign, UL have been linked to malignancy through two genomic regions on chromosome 1.
  • Mutation of fumarate hydratase (FH) at 1q43 is known to cause the Mendelian syndromes of multiple cutaneous and uterine leiomyomata (MCL) and hereditary leiomyomatosis and renal cell cancer (HLRCC), and recently, FH mutations have been detected in some non-syndromic UL.
  • In addition, transcriptional profiling suggests that loss of the short arm of chromosome 1 in cellular leiomyomata, an uncommon histological variant of UL, may account in part for the presumed yet rare malignant transformation of UL to uterine leiomyosarcoma.
  • [MeSH-major] Leiomyoma / genetics. Leiomyosarcoma / genetics. Uterine Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613550.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA078895; United States / NICHD NIH HHS / HD / R01HD046226; United States / NIGMS NIH HHS / GM / T32GM007748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  • [Number-of-references] 78
  •  go-up   go-down


15. Di Giacomo A, Danielli R, Calabrò L, Guidoboni M, Miracco C, Biagioli M, Mazzei M, Altomonte M, Maio M: Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20002 Background: Effective anti-tumor responses are being observed in metastatic melanoma (MM) patients (pts) with the anti-CTLA-4 antibody Ipilimumab (Ipi) in clinical trials; however no data support the feasibility and clinical effectiveness of Ipi use in the daily practice.
  • Eight pts had evidence (6) or history (2) of brain metastases and 11 elevated (>1x upper limit of normal [ULN]) LDH.
  • Tumor assessment (TA) per modified World Health Organization criteria was performed at baseline, week (wk) 12 (±2) and wk 24, then every 12 wks.
  • TA at wk 12 showed partial response (PR) in 1/18 or stable disease (SD) in 5/18 pts.
  • TA at wk 24 showed PR and SD in 3/8 and 5/8 pts, respectively, with an ongoing clinical benefit (SD + PR + CR) of 34% (8/23 pts); these pts are still on treatment.
  • Slow, steady declines in tumor volume and appearance of new lesions with subsequent shrinking of total tumor burden has been observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Doyen J, Italiano A, Largillier R, Ferrero J, Fontana X, Thyss A: Aromatase inhibition in male breast cancer patients: Biological and clinical implications. J Clin Oncol; 2009 May 20;27(15_suppl):1130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here the largest experience about the efficacy of AI in MBC pts with advanced disease and their impact on estradiol (E) levels.
  • METHODS: MBC pts were selected from the breast cancer database of the Centre Antoine-Lacassagne (Nice, France) as follows: Metastatic disease with at least one measurable or assessable non-measurable lesion, estrogen receptor (ER) and/or or progesterone receptor (PR) positive, availability of complete clinical and histological data, evidence of progressive disease at initiation of AI, receipt of at least one month of treatment with non steroidal (anastrozole, letrozole) or steroidal (exemestane) AI.
  • Sex hormone levels were retrospectively assessed on serum samples from our institutional serum bank.
  • 9 out of 11 pts with available samples had E levels less than the lower limit of the assay during AI treatment.
  • Among the 9 pts with E level decrease, four had OR, one had SD, and four had PD.
  • 1 pt had E levels higher than the upper limit of the assay during AI treatment.
  • Further data on FSH and testosterone levels will be presented at the meeting.
  • This activity is correlated with a significant reduction in E levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962244.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Maurel J, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Garcia-Albeniz X, Muñoz J, Fernandez-Martos C, Carcereny E, Castellví-Bel S: EGFR polymorphism and KRAS mutational status as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study. J Clin Oncol; 2009 May 20;27(15_suppl):4060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, a significant increment on RR (30 vs. 0%, p=0.003), PFS (14.4 vs. 7.4 w, p=0.002) and OS (34.1 vs. 20 w, p=0.03) was observed only in those patients with WT KRAS and >1x upper limit of normal (ULN) lactate dehydrogenase (LDH) levels compared with mutant KRAS, but these differences were not found in pts with WT KRAS and <1xULN levels of LDH: [RR (14 vs. 14%, p=NS), PFS (14.4 vs. 13.1 w, p=NS) and OS (31 vs. 31 w; p=NS)].
  • Our study suggest that pts with WT KRAS and >1xULN levels of LDH, have major benefit to anti-EGFR therapy in second-third line therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Tolcher AW, Yap TA, Fearen I, Taylor A, Carpenter C, Brunetto AT, Beeram M, Papadopoulos K, Yan L, de Bono J: A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol; 2009 May 20;27(15_suppl):3503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).
  • MK-2206, a highly selective non-ATP competitive allosteric Akti, has nM IC<sub>50</sub> and broad preclinical antitumor activity.
  • Main eligibility criteria: ≥18 yo, evaluable advanced ST, ECOG ≤1, HbA1c ≤8% or fasting glucose ≤110% upper limit of normal.
  • Sequential tumor biopsies were performed in a subset of pts.
  • Evidence of PD activity included decreases in whole blood pAkt at all dose levels, reversible CTCAE G1/2 hyperglycemia and CTCAE G1 insulin c-peptide elevations.
  • Observed clinical activity included: central tumor necrosis, decreased ascites and peripheral edema, reduction in index lesions, normalization of LFTs, and decreased CA-125.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961284.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rodriguez Franco C, Aguiar Bujanda D, Saura Grau S, Bohn Sarmiento U, Aguiar Morales J: Male breast cancer retrospective institution review of a 17-year period. J Clin Oncol; 2009 May 20;27(15_suppl):e11638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ductal carcinoma was the predominant histologic subtype with 17 patients (77%).
  • CONCLUSIONS: MBC in our area are in the upper limit of occidental countries incidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961210.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Heng DY, Xie W, Regan MM, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott D, Rini BI, Choueiri TK: Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):5041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study.
  • Four of the five PFs previously identified by MSKCC were independent predictors of short survival, including hemoglobin below the lower limit of normal (LLN) (p < 0.0001), corrected calcium above the upper limit of normal (ULN) (p = 0.0006), Karnofsky performance status <80% (p < 0.0001) and time from initial diagnosis to initiation of therapy ULN (pULN (p = 0.012) were independent adverse PFs.
  • This model derived from a large population can be incorporated into patient care and clinical trials of VEGF-targeted agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).
  • It is active as a single agent and in combination with R in NHL tumor models.
  • The best ORR is at the upper limit of reported ORR for R alone; therefore a randomized trial is required to definitively determine activity of the combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tsai DE, Wang W, Reshef R, Vogl D, Stadtmauer E, Andreadis C, Carlson A, Luger S: Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e20533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed platelet count data from 3 Bex clinical trials encompassing non-small cell lung cancer (NSCLC) and AML.
  • More patients on Bex than on placebo had an increase in platelet count of at least 50 K/uL (55% vs. 27% for CarP, p<0.0001; 81% vs. 66% for CisV, p<0.0001) over pre-treatment baseline.
  • The median increase in platelet count was higher on Bex than on placebo (69 vs 0 K/uL for CarP, p<0.0001; 168 vs. 95 K/uL for CisV, p<0.0001) and was maintained while on treatment.
  • In both NSCLC trials, the median time to platelet increase >50 K/uL on Bex was 22 days.
  • Similar findings were seen in a phase I monotherapy trial in AML where 5/18 (28%) patients achieved platelet transfusion independence with peak platelet counts of 40-91 K/uL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Sawyer MB, Damaraju S, Pituskin E, Damaraju V, Scarfe AG, Bies RB, Hanson J, Clemons M, Kuzma M, Mackey JR: Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression. J Clin Oncol; 2009 May 20;27(15_suppl):2504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PTS with ALT and AST ≤ upper limit of normal (ULN), a total bilirubin ≤ ULN, and normal renal and cardiac function were eligible.
  • EPI levels were drawn at approximately 1 and 24 hrs.
  • CONCLUSIONS: A SNP in UGT 2B7 is common and appears to predicts EPI clearance and myelosuppresion in non-metastatic breast cancer PTS and may form the basis for a method to individualize EPI treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ohashi Y, Watanabe T, Sano M, Koyama H, Inaji H, Suzuki T: Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial). J Clin Oncol; 2009 May 20;27(15_suppl):578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One study was the N-SAS-BC01 trial (Watanabe et al, J Clin Oncol, in press), conducted in patients with node-negative, high-risk breast cancer.
  • Hazard ratios (HR) were determined with the Cox regression stratified by study and adjusted for the clinical characteristics of age, tumor size, nodal status, histological type, ER and PgR.
  • Non-inferiority of UFT was concluded if the upper limit of two-sided CI for the HR of RFS did not exceed 1.30; the significance level of CI was determined by the Hochberg multiplicity adjustment (alpha=0.05:two sided).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960748.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Cereda S, Rognone A, Ghidini M, Rezzonico S, Passoni P, Mazza E, Nicoletti R, Zerbi A, Villa E, Reni M: A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):4614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cycles were repeated every 14 days for a maximum of 6 months.
  • Tumor was assessed by CT scan every 8 weeks.
  • Patients' characteristics were (A/B): median age 61/59, PS > 70 92/88%, metastatic disease 66/65%; CA19.9 > upper limit of laboratory normal (ULN) 87/90%, median CA19.9 820/755 UI/mL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tryakin A, Fedyanin M, Bulanov A, Titov D, Allakhverdiyeva G, Mitin A, Sergeev J, Zaharova T, Garin A, Tjulandin S: Prognostic factors in advanced seminoma in the era of etoposide- and cisplatin-based chemotherapy: Importance of pretreatment LDH-level. J Clin Oncol; 2009 May 20;27(15_suppl):e16038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced seminoma in the era of etoposide- and cisplatin-based chemotherapy: Importance of pretreatment LDH-level.
  • : e16038 Background: The commonly used IGCCCG classification probably underestimates other prognostic factors (tumor markers, stage) for advanced seminoma, which was shown later (Fossa S., 1997).
  • 227 (91%) pts had primary testicular tumor, 241 (96%) pts belonged to IGCCCG good prognostic group.
  • Univariate analysis revealed following factors as significant: number of metastatic sites, presence of pulmonary metastases, RPLN size, hCG level, and LDH level.
  • Using cut-off 2 x upper limit of normal for LDH level, "modern CT" group can be divided into favorable (105 [60%] pts) and unfavorable (69 (40%) pts) groups with 5-years DFS 98% vs. 78% (HR 11.1, 95% CI 3.2-33.3) and 5-years OS 99% vs. 80% (HR 11.07, 95% CI 3.09-27.92), respectively.
  • Pre-treatment LDH level is an important independent prognostic factor, which could help stratify pts better into risk groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Weese J, Sandhu PD, Mody A, Ozer H, Jafari M, Tfayli AH, Kojouri K: Assessment of diabetes mellitus (DM) as a risk factor for development of cisplatin-induced nephrotoxicity (CIN). J Clin Oncol; 2009 May 20;27(15_suppl):e13537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DM was diagnosed if pt had (1) been taking anti-diabetic treatment, or (2) Hgb A1C ≥6.5%, or (3) ≥2 fasting outpatient serum glucose levels 126-199 mg/dl, or (4) ≥1 serum glucose level ≥200 mg/dl at any time, prior to receiving cisplatin.
  • CIN was defined as increase in serum creatinine (SCr) by ≥50% above baseline and higher than upper limit of normal, after exclusion of other causes of elevated SCr, during or within 8 weeks of completion of treatment.
  • Odds ratio (OR) was calculated to compare risk of CIN between diabetics and non-diabetics.
  • Distribution of age (years, diabetics: 62 [46-77]; non-diabetics: 60 [26-79], p = 0.18) and baseline SCr (mg/dl, diabetics: 1.0 [0.4-1.5]; non-diabetics: 1.0 [0.5-1.6], p = 0.86) were similar between the two groups.
  • Risk of CIN was not different between diabetics (8 of 50 pts, 16%) and non-diabetics (22 of 150 pts, 14.7%); OR = 1.11 (95% CI = 0.46 to 2.67) (Table).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Koul M, Mahurkar S, Legendre B, Jiang J, Kaldjian E: High-sensitivity KRAS mutation detection in colorectal and lung cancer using SURVEYOR Nuclease scanning. J Clin Oncol; 2009 May 20;27(15_suppl):e22023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Levels of mutant DNA as low as 2% (1 ng/ul) were identified by this method, consistent with other SURVEYOR-based assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963131.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Govindarajan R, Siegel E, Makhoul I, Williamson S: Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):e15557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pre-determined endpoint for a positive result is a 27 week PFS of > 20%.
  • METHODS: A phase II study was conducted for newly diagnosed unresectable or metastatic HCC, Child-Pugh class A or B cirrhosis with bilirubin <2.0 mg/dL, transaminases < 5 x ULN, Platelet count >75,000 K/UL and ECOG PS 0-2 who had no prior systemic therapy and were not candidates for liver transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962331.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Crowley J, Bolejack V, Robert K, Anderson K, Barlogie B: Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival. J Clin Oncol; 2009 May 20;27(15_suppl):8599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We therefore examined, in S9321, PF that were associated with overall survival (OS) from baseline (BL) and from 3 subsequent landmarks 3, 5, and 7 years later (LM3, LM5, LM7).
  • The BL model identified age (>60yr), hemoglobin (<10g/gL), platelet count (<130,000/uL), albumin (<3.5g/dL), B2M (>3.5g/dL), calcium (>10mg/dL), creatinine (>2mg/dL), LDH (>190U/L), performance status (PS, >1), IL-6 level (>140mg/L) and plasma cell labeling index (PCLI, >1%) as being univariately associated with short OS, while age (p=0.002), platelet count (p=0.04), calcium (p<0.001), B2M (p=0.002), LDH (p=0.010) and PCLI (p<0.001) retained significance in multivariate analysis.
  • While associated univariately with OS from BL, CRP, platelet count, hemoglobin, albumin, calcium, creatinine, LDH, IL6 and PS all failed to affect OS from later LM times.
  • CONCLUSIONS: Whereas the initial 3 years of OS are governed by a combination of features related to disease aggressiveness (LDH, calcium, albumin, CRP), tumor burden (hemoglobin, platelet count) and host tolerance (PS, creatinine), B2M and PCLI as reflectors of tumor burden and proliferation have sustained long-term OS implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Hong M, Jeung H, Chung H, Ahn J, Roh J, Noh S, Rha S: Predictive factors associated with clinical outcome and safety in Korean patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol; 2009 May 20;27(15_suppl):e16111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor response was evaluated according to the RECIST criteria, and safety was assessed by NCI-CTC (version 3.0).
  • Performance status (ECOG 0-1) and corrected Ca level (8.5∼10.5 mg/dl) were associated with favorable ORR (P=.038) and DCR (p=0.008), respectively.
  • Predictive factors for grade 3/4 thrombocytopenia were corrected Ca level (P=.018), poor MSKCC risk group (P=.025), and low WBC count (<4500/ul, P=.041).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Ruan J, Martin P, Coleman M, Furman R, Glynn P, Joyce M, Cheung K, Shore T, Schuster M, Leonard J: Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL). J Clin Oncol; 2009 May 20;27(15_suppl):8525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8525 Background: Targeting tumor microenvironment and angiogenesis is a novel therapeutic strategy in lymphoma.
  • A maintenance phase (mo 4 until progression) continues with daily thalidomide (100 mg), PEPC dosing titrated to ANC > 1K/ul, and rituximab q 4 months.
  • Translational studies assessed the angiogenic phenotypes of tumor cells, and dynamic levels of circulating endothelial and hematopoietic progenitors in response to treatment.
  • At a median followup of 30 months, overall response rate was 73% (32% CR/CRu, 41% PR, N=22).
  • Correlative studies demonstrated pre-therapy autocrine angiogenic loop in tumor cells evidenced by expression of VEGFA and VEGFR1.
  • Circulating levels of hematopoietic and endothelial progenitor cells decreased on rx in responders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960902.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Drullinsky P, Fornier MN, Sugarman S, D'Andrea G, Troso-Sandoval T, Seidman AD, Yuan J, Patil S, Norton L, Hudis C: Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary end point was feasibility defined as having ANC > 1.5 x 10<sup>3</sup>/uL on day 1 of planned treatment for all 8 cycles with no grade 3 or higher non-hematologic toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Hollmig K, Waheed S, Nair B, Haessler J, Petty N, Pineda-Roman M, Alsayed Y, van Rhee F, Crowley J, Barlogie B: MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3. J Clin Oncol; 2009 May 20;27(15_suppl):8595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis of features associated with transient and persistent MDS-CA revealed TT3 as an adverse feature (HR=2.84, p=0.043), along with incomplete platelet recovery of <165,000/uL 3mo after 1<sup>st</sup> transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962291.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Reni M, Cereda S, Aprile G, Tronconi MC, Milandri C, Passoni P, Rognone A, Balzano G, Di Carlo V, Villa E: A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients' characteristics were (A/B): median age 61/60, median PS 90/90, stage IIA 19/12%; stage IIB 73/81%; stage III 8/7%; grade 3 30/46; R1 36/30; pre- and post-surgery surgery CA19.9 > upper limit of laboratory normal 68/80% and 29/33%, tumor size > 2.9 cm 41/43%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Dwary AD, Sharma A, Mohanti BK, Pal S, Garg P, Raina V, Shukla NK, Deo SV, Thulkar S, Sreenivas V: A randomized controlled trial (RCT) comparing best supportive care (BSC), 5-FU plus folinic acid (FUFA) and, gemcitabine plus oxaliplatin (Gem-Ox) in management of unresectable gallbladder cancer (GBC). J Clin Oncol; 2009 May 20;27(15_suppl):4521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were: proven unresectable GBC, performance state ≤2, adequate bone marrow reserve and normal biochemical profile (bilirubin≤3 mg % & liver enzymes within 5 times of upper limit).
  • In FUFA group, weekly bolus doses of 5-FU (425mg/m2) plus Folinic acid (20 mg/m2) were given for a maximum of 30 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962726.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kaseb AO, Iwasaki M, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, Thomas MB: Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4522 Purpose: HCC is the fifth most common solid tumor worldwide and the incidence is rising in western countries.
  • PATIENTS AND METHODS: Eligibility criteria include biopsy-proven unresectable HCC, Child-Pugh class A or B cirrhosis, bilirubin ≤2.0 mg/dL, transaminase (TA) levels ≤5 times the upper limit of normal, platelets ≥50,000/μL and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962725.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Arellano ML, Winton E, Pan L, Souza L, Sunay S, Lima L, McLemore M, Heffner LT, Langston A, Khoury HJ: Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
  • : 7070 Background: In contrast to the poor prognosis associated with hyperleukocytosis, the prognostic significance of leukopenia at the time of diagnosis of AML is unknown.
  • METHODS: Single institution retrospective analysis of 225 consecutive, newly diagnosed AML patients (pts), homogeneously treated between July 1996 and February 2005; and divided into 2 groups based on presenting WBC: < 2,000/uL (30) and > 2,000/uL (195).
  • RESULTS: Patients' characteristics (gender, secondary vs. de novo, and cytogenetic [CTG] risk) were comparable between the 2 groups.
  • Induction mortality was 0% for leukopenic and 5% for non-leukopenic pts.
  • In primary refractory pts, median survival was longer for leukopenic (11) vs. non-leukopenic (34) pts: 137 vs. 81 d (p = 0.026).
  • The level of expression of cell surface adhesion molecules on blood and marrow blasts was comparable for the 2 groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Lobel MK, Somasundaram P, Morton CC: The genetic heterogeneity of uterine leiomyomata. Obstet Gynecol Clin North Am; 2006 Mar;33(1):13-39
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genetic heterogeneity of uterine leiomyomata.
  • Research investigating the genetics of UL has already been successful in gathering epidemiologic evidence for heritability, establishing the clonal and mosaic nature of these tumors, correlating genotypic and phenotypic characteristics, defining cytogenetic subgroups, and identifying specific genes involved in tumorigenesis.
  • Although UL are known to be benign tumors, the impact they have on the lives of so many women can only be described as "malignant".
  • For this reason, continuing the quest to ascertain the genes, functions, and mechanisms integral to UL development is absolutely imperative.
  • Genetic tests for personalized medical management of women with fibroids is at the threshold for providing the most appropriate treatments (Fig.
  • 3), and combined with developing less invasive therapies portends a brighter future for a major health problem for women.
  • [MeSH-major] Leiomyoma / genetics. Uterine Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504804.001).
  • [ISSN] 0889-8545
  • [Journal-full-title] Obstetrics and gynecology clinics of North America
  • [ISO-abbreviation] Obstet. Gynecol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA78895
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 185
  •  go-up   go-down


40. Lupattelli T, Clerissi J, Basile A, Minnella DP, Donati Sarti R, Gerli S, Di Renzo G: [Treatment of uterine fibromyoma with bilateral uterine artery embolization: state of the art]. Minerva Ginecol; 2007 Aug;59(4):427-39
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of uterine fibromyoma with bilateral uterine artery embolization: state of the art].
  • [Transliterated title] Trattamento di fibromioma dell'utero mediante embolizzazione bilaterale dell'arteria uterina. Stato dell'arte.
  • Uterine fibroids are common tumors of the female pelvis.
  • Uterine artery embolization (UAE) is a minimally invasive alternative procedure in appropriate candidates to conventional myomectomy and hysterectomy for symptomatic uterine leiomyoma, reducing or eliminating leiomyoma-related symptoms of bleeding, bulk, and/or pain.
  • In order to completely block the arterial blood supply to the fibroid, UAE is typically performed in both uterine arteries.
  • At 1 year follow-up, the uterus may shrink by up to 55%, however, a re-growth of the fibroid may occur.
  • Despite the lack of controlled studies that compared UAE with conventional surgery, and despite limited extended outcome data, UAE has gained rapid acceptance, primarily because this procedure preserves the uterus, is less invasive, and has less short-term morbidity than most surgical options.
  • [MeSH-major] Embolization, Therapeutic / methods. Leiomyoma / therapy. Uterine Neoplasms / therapy. Uterus / blood supply

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923833.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 72
  •  go-up   go-down


41. López Cervantes G, Vega Ruiz FJ, Peralta Velázquez V: [Epithelioid uterine leiomyoma with giant cystic degeneration. A case report]. Ginecol Obstet Mex; 2009 Aug;77(8):376-9
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid uterine leiomyoma with giant cystic degeneration. A case report].
  • [Transliterated title] Leiomioma uterino epitelioide con degeneración quística gigante. Reporte de un caso.
  • At present, show woman 46-years-old, presented hiperpolimenorrea, pelvis ultrasound appearance with cystic giant mass in the uterine corpus; histopathological revealed a epithelioid leiomyoma with giant cystic degeneration.
  • We considered it is the first reported case of this variant of the epithelioid leiomyoma.
  • [MeSH-major] Cysts / etiology. Cysts / pathology. Leiomyoma, Epithelioid / complications. Uterine Diseases / etiology. Uterine Diseases / pathology. Uterine Neoplasms / complications

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902628.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


42. Dragomir AD, Schroeder JC, Connolly A, Kupper LL, Hill MC, Olshan AF, Baird DD: Potential risk factors associated with subtypes of uterine leiomyomata. Reprod Sci; 2010 Nov;17(11):1029-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential risk factors associated with subtypes of uterine leiomyomata.
  • OBJECTIVE: To compare potential risk factors for uterine leiomyomata (UL) subtypes among premenopausal African American and Caucasian women.
  • METHODS: This cross-sectional study included 986 premenopausal women, aged 35 to 49 years old, from the National Institute of Environmental Health Sciences (NIEHS) Uterine Fibroid Study (UFS).
  • Uterine leiomyomata were subtyped as submucosal, intramural/subserosal, and diffuse, based on ultrasound examinations.
  • RESULTS: For both ethnic groups, age, age at menarche, body mass index, and current physical activity had similar associations across the 3 UL subtypes.
  • Inverse associations with pregnancies after age 24 appeared to be stronger for the submucosal subtype.
  • Current smoking was associated only with diffuse UL (adjusted odds ratio [aOR] = 1.97, 95% CI: 1.11, 3.51 in African Americans, aOR = 3.00, 95% CI: 1.07, 8.38 in Caucasians).
  • CONCLUSIONS: Although the 2 focal UL subtypes had similar risk factor profiles, the diffuse UL subtype appeared to have a distinctive risk profile with regard to current smoking.
  • Further study of the diffuse heterogeneity seen with uterine ultrasound is needed.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693498.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD050924; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


43. Surmacki P, Sporny S, Tosiak A, Lasota J: Disseminated peritoneal leiomyomatosis coexisting with leiomyoma of the uterine body. Arch Gynecol Obstet; 2006 Feb;273(5):301-3
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated peritoneal leiomyomatosis coexisting with leiomyoma of the uterine body.
  • The authors present an extremely rare case of disseminated peritoneal leiomyomatosis (DPL) coexisting with leiomyoma of the uterine body in a 32-year-old woman.
  • Before the present surgery leiomyoma of the left corner of the uterine body was diagnosed.
  • DPL was found on the uterine serous membrane, Douglas's cavity, vesicouterine recess, the great omentum and abdominal peritoneum.
  • Saving operation was performed and only leiomyoma and the great omentum were resected.
  • Immunohistochemical analysis using smooth muscle actin and HHF-35 antibodies showed the same reactivity of leiomyoma and DPL cells and proved the intra-operative diagnosis.
  • That both leiomyoma and DPL are hormonally dependent could also be proved.
  • [MeSH-major] Leiomyoma / diagnosis. Leiomyomatosis / diagnosis. Neoplasms, Multiple Primary / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341539.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Mencalha AL, Levinsphul A, Deterling LC, Pizzatti L, Abdelhay E: SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Mol Med Rep; 2008 Jul-Aug;1(4):571-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC-like1 mRNA is overexpressed in human uterine leiomyoma.
  • Uterine leiomyomas (ULs), also known as fibroids, are benign and monoclonal tumors frequently found in the female population.
  • The genetic alterations that contribute to UL tumor development have not been well established, and the goal of this study was to reveal gene expression variation between ULs and healthy uterine tissue.
  • We compared the gene expression profiles of 13 UL tumors with that of their adjacent normal tissue using the Differential Display mRNA assay (DDRT-PCR).
  • Among the genes upregulated in some of the UL samples, several genes previously described in the context of cancer were identified, namely LIMK1, MCM3 and UHRF1.
  • In addition, we identified a cDNA present in UL samples from distinct patients, which was absent from their normal tissue.
  • Through semi-quantitative PCR, we demonstrated that SPARCL1 was upregulated in approximately 77% of UL samples, but was absent in normal tissue.
  • Real-time PCR (QPCR) revealed that SPARCL1 expression was increased 5-fold in ULs compared to adjacent normal tissue.
  • These results suggest that the SPARCL1 gene is involved in UL development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479452.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


45. Chen Z, Wang C, Pu D, Hu J, Chen L: Ultra-large multi-region photon sieves. Opt Express; 2010 Jul 19;18(15):16279-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultra-large multi-region photon sieves.
  • A novel method of designing ultra-large photon sieves in visible regime with multi-region structure is proposed and experimentally demonstrated.
  • The extension of the proposed method suggests a new concept of ring-to-ring design in terms of pinhole size and density of each individual ring for photon sieves with superior suppressed sidelobes towards ultra-large dimension, high numerical aperture that can be implemented with UV lithography which is otherwise impossible with e-beam technique.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721014.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Lorch PD: Using upper limits of "bateman gradients" to estimate the opportunity for sexual selection. Integr Comp Biol; 2005 Nov;45(5):924-30
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using upper limits of "bateman gradients" to estimate the opportunity for sexual selection.
  • After demonstrating the need for a new measure, I develop one based on the upper limit on sexual selection.
  • I describe what sets the upper limit for each sex by showing how maximum fecundity increases with number of mates, accounting for the amount of energy (or critical resources) available for reproduction and levels of parental care.
  • For females the upper limit on sexual selection is set by the value of paternal investment that comes with each mating.
  • For males, the upper limit on sexual selection is set by the fecundity of their mates (including any boost to female fecundity from paternal investment).
  • Sex-roles are most likely to reverse (making males choosy and females competitive) when the amount of reproductive energy investment made by each sex is low, irrespective of the level of paternal investment.
  • Finally, I propose that we use the difference between male and female upper limits on sexual selection to quantify sex differences in the opportunity for sexual selection.
  • Using upper limits to estimate the opportunity for sexual selection is more intuitive than older methods (e.g., standardized variance in mating success), it is experimentally measurable, and it is valuable in understanding the evolution of mating systems.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21676843.001).
  • [ISSN] 1540-7063
  • [Journal-full-title] Integrative and comparative biology
  • [ISO-abbreviation] Integr. Comp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Briceño Pérez C, Briceño Sanabria L, Briceño Sanabria J, Briceño Sanabria C: [Vaginal leiomyoma]. Ginecol Obstet Mex; 2006 May;74(5):277-81
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vaginal leiomyoma].
  • [Transliterated title] Leiomioma vaginal.
  • Vaginal leiomyomas are rare benign tumors.
  • [MeSH-major] Leiomyoma. Vulvar Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972526.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 17
  •  go-up   go-down


48. Krehbiel CR, Cranston JJ, McCurdy MP: An upper limit for caloric density of finishing diets. J Anim Sci; 2006 Apr;84 Suppl:E34-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An upper limit for caloric density of finishing diets.
  • This review assessed the relationships between dietary energy density and animal performance in an effort to evaluate a possible upper limit for energy density in finishing diets for cattle.
  • Data were combined from 49 experiments (69 trials; 243 treatment observations) in which the dietary ME concentration (Mcal/kg of DM) was varied by level of concentrate, grain source, grain processing, and level of supplemental fat.
  • However, the slope of ME intake (Mcal/kg of BW(0.75)) vs. dietary ME content did not differ (P > 0.25) from zero, supporting the concept that ruminants on high-grain diets (2.7 to 3.3 Mcal of ME/kg of DM) eat to maintain constant energy intake.
  • Assuming that NRC ME values for ingredients commonly used in finishing diets are correct, the upper caloric limit for maximizing ADG and G:F was 3.16 and 3.45 Mcal/kg of DM, respectively.
  • Reaching the upper caloric limit for G:F would require most grains to be processed or fed in high-moisture form.
  • [MeSH-major] Cattle / growth & development. Diet / veterinary. Energy Intake / physiology. Energy Metabolism / physiology
  • [MeSH-minor] Animals. Body Weight / physiology. Dietary Fats / analysis. Edible Grain / metabolism. Edible Grain / standards. Food Handling. Weight Gain / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16582091.001).
  • [ISSN] 1525-3163
  • [Journal-full-title] Journal of animal science
  • [ISO-abbreviation] J. Anim. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Number-of-references] 66
  •  go-up   go-down


49. Tozo IM, Moraes JC, Lima SM, Gonçalves N, Auge AP, Rossi LM, Aoki T: [Sexuality evaluation in women submitted to hysterectomy for the treatment of uterine leiomyoma]. Rev Bras Ginecol Obstet; 2009 Oct;31(10):503-7
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sexuality evaluation in women submitted to hysterectomy for the treatment of uterine leiomyoma].
  • [Transliterated title] Avaliação da sexualidade em mulheres submetidas à histerectomia para tratamento do leiomioma uterino.
  • PURPOSE: To evaluate the impact of hysterectomy on the sexuality of women with uterine leiomyoma.
  • [MeSH-major] Hysterectomy / adverse effects. Leiomyoma / physiopathology. Leiomyoma / surgery. Sexual Dysfunction, Physiological / etiology. Sexuality. Uterine Neoplasms / physiopathology. Uterine Neoplasms / surgery


50. Acebal P, Blaya S, Carretero L, Fimia A: Upper limits of dielectric permittivity modulation in bacteriorhodopsin films. Phys Rev E Stat Nonlin Soft Matter Phys; 2005 Jul;72(1 Pt 1):011909

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limits of dielectric permittivity modulation in bacteriorhodopsin films.
  • Analysis of dielectric permittivity modulation enables us to determine the fundamental limits of BR to be used in a holographic data storage system, together with the optimum experimental and material conditions.
  • The theoretical upper limits of Deltaepsilson at 750 nm (far from the resonance of the molecule) in a randomly oriented material are about 0.01 and 0.012 for B--> M and B--> Q transitions, respectively.
  • The highest eta is produced for a hologram thickness in the range of 900-1000 microm and working wavelength of 700-750 nm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16090003.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polymers; 0 / Schiff Bases; 53026-44-1 / Bacteriorhodopsins
  •  go-up   go-down


51. Hong SM, Cha CI, Park BR: Changes in calbindin expression within the flocculus after unilateral labyrinthectomy in rats. Neurosci Lett; 2009 Aug 21;460(1):52-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in calbindin expression within the flocculus after unilateral labyrinthectomy in rats.
  • Expression of calbindin in flocculus was examined using immunohistochemistry following unilateral labyrinthectomy (UL) in rats.
  • Both the staining intensity and number of calbindin-positive Purkinje cells in the ipsilateral flocculus to the lesion side decreased 6h after UL compared to the control and contralateral side.
  • Forty-eight hours after UL, the expression of calbindin returned to control levels and asymmetric expression in bilateral flocculus subsided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446007.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Calbindins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


52. Carriquiry AL, Camaño-Garcia G: Evaluation of dietary intake data using the tolerable upper intake levels. J Nutr; 2006 Feb;136(2):507S-513S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of dietary intake data using the tolerable upper intake levels.
  • We discuss the problem of assessing nutrient intake relative to the tolerable upper intake levels (UL) for the nutrient proposed by the Institute of Medicine and focus on 2 important topics: the estimation of usual nutrient intake distributions and the extent to which intakes above the UL can be considered risky.
  • Thus, intakes above UL cannot be declared to be unsafe.
  • Intakes below the UL, however, are likely to pose no risk to individuals in the group.
  • Because determining the proportion of individuals with intakes below the UL requires estimation of an upper-tail percentile of the intake distribution, the use of 1-d intake data or otherwise unadjusted intake data are likely to lead to severely biased estimates.
  • It is important to remove within-individual variance in intakes from daily intakes so that the tails of the usual intake distribution are accurately estimated.
  • Underreporting of the amount of nutrients consumed will tend to shift the estimated usual nutrient intake distribution downwards.
  • In this case, the true proportion of individuals with intakes below the UL is likely to be overestimated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424136.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


53. Zhang Y, Kong W, Hu Y: [Expression change of mGluR5 in rat MVN after unilateral labyrinthectomy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 May;23(10):456-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression change of mGluR5 in rat MVN after unilateral labyrinthectomy].
  • OBJECTIVE: To observe the expression of mGluR5 in the medial vestibular nucleus (MVN) following unilateral labyrinthectomy (UL).
  • Twenty four animals received unilateral labyrinthectomy while the others maintained labyrinthine well.
  • RESULT: mGluR5 was increased in lesioned side MVN after unilateral labyrinthectomy.
  • The 12 h post-UL was highest.
  • Then it was decrease in 36 h post-UL, while 7 d post-UL was same as control group.
  • CONCLUSION: UL can induce increase of mGluR5 in the MVN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670629.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Grm5 protein, rat; 0 / Receptor, Metabotropic Glutamate 5; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


54. Lee JH, Ameer AN, Choi MA, Lee MY, Kim MS, Park BR: Recovery of vestibulogastrointestinal symptoms during vestibular compensation after unilateral labyrinthectomy in rats. Otol Neurotol; 2010 Feb;31(2):241-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recovery of vestibulogastrointestinal symptoms during vestibular compensation after unilateral labyrinthectomy in rats.
  • BACKGROUND: The loss of unilateral vestibular function causes vestibulogastrointestinal symptoms that include nausea and vomiting.
  • Thus, the temporal changes and the role of the cerebellum in the recovery of vestibulogastrointestinal symptoms after unilateral labyrinthectomy (UL) were investigated in this study.
  • These were measured at 30 minutes and at 2, 6, and 24 hours after UL in rats.
  • RESULTS: Intestinal transit was 66.3% +/- 7.6% in the control animals but significantly decreased to 40.7% +/- 7.8%, 46.3% +/- 6.3%, and 48.6% +/- 10.8% at 30 minutes (p < 0.01), 2 hours (p < 0.01), and 6 hours (p < 0.05) after UL, respectively.
  • The intestinal transit showed a recovery to control levels 24 hours after UL.
  • The geometric center was 5.6 +/- 0.4 in control animals but significantly decreased to 2.1 +/- 0.4, 2.9 +/- 0.3, and 4.0 +/- 0.3 at 30 minutes, 2 hours, and 6 hours after UL, respectively (p < 0.01).
  • Recovery of the geometric center to control levels, 24 hours after UL, was reported.
  • Moreover, UL in uvulonodullectomized animals significantly decreased the intestinal transit and geometric center for 24 hours after surgery (p < 0.01).
  • Pretreatment of the UL animals with MK-801 significantly increased the geometric center 30 minutes after surgery (p < 0.01).
  • Unilateral labyrinthectomy produced spontaneous nystagmus, 28.9 +/- 1.5, 23.3 +/- 1.4, 17.5 +/- 1.5, and 9.2 +/- 0.9 beats per 10 seconds at 30 minutes and at 2, 6, and 24 hours after UL, respectively.
  • Expression of the c-Fos protein was significantly increased in the medial vestibular nuclei and inferior vestibular nuclei at 1, 2, and 6 hours after UL, and the expression was significantly decreased in animals that were pretreated with MK-801 (p < 0.01).
  • CONCLUSION: These results suggest that the recovery of vestibulogastrointestinal symptoms is faster than that of vestibulo-ocular symptoms and that the cerebellum and glutamate have an important role to play in the recovery of symptoms after UL.
  • [MeSH-major] Ear, Inner / physiology. Ear, Inner / surgery. Gastrointestinal Diseases / physiopathology. Vestibular Diseases / physiopathology. Vestibule, Labyrinth / physiology

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Otol Neurotol. 2010 Jun;31(4):705
  • (PMID = 20101163.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Antagonists; 0 / Proto-Oncogene Proteins c-fos; 3KX376GY7L / Glutamic Acid; 6LR8C1B66Q / Dizocilpine Maleate
  •  go-up   go-down


55. Tsuji J, Murai N, Naito Y, Ito J: c-Fos expression in the mouse brainstem after unilateral labyrinthectomy. Acta Otolaryngol Suppl; 2007 Feb;(557):8-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Fos expression in the mouse brainstem after unilateral labyrinthectomy.
  • CONCLUSION: The results indicated that the vestibular, prepositus hypoglossal, and inferior olive nuclei were activated after unilateral labyrinthectomy in mice like in other species.
  • Previous reports, investigating c-Fos expression after unilateral labyrinthectomy were made in rats and guinea pigs, but not in the mouse brainstem.
  • MATERIALS AND METHODS: For future application to the gene knockout mouse, we examined c-Fos expression in the mouse after unilateral labyrinthectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453434.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


56. Galani P, Kapetanakis S, Papadopoulos C, Dimitrakopoulou G, Kosma L, Lafoyianni S, Dimitrakova E, Papathanasiou J, Fiska A: Hypovolemic shock due to giant uterus leiomyoma detachment. Akush Ginekol (Sofiia); 2010;49(5):68-71
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypovolemic shock due to giant uterus leiomyoma detachment.
  • Uterine leiomyoma (UL) is the most common benign gynecologic tumor of the reproductive age females.
  • In this study, we report a 50-year-old woman with a giant mass, attached to the uterus, which was detached and therefore led to shock due to major hemorrhage.
  • Surgical removal of both the mass and the uterus confirmed the diagnosis of a pedunculated uterine leiomyoma.
  • [MeSH-major] Hypovolemia / etiology. Leiomyoma / complications. Uterine Neoplasms / complications
  • [MeSH-minor] Female. Humans. Middle Aged. Uterus / pathology. Uterus / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21265397.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


57. Nicoletti S, Battevi N: [Upper-limb work-related musculoskeletal disorders (UL-WMSDs) and latency of effect]. Med Lav; 2008 Sep-Oct;99(5):352-61
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upper-limb work-related musculoskeletal disorders (UL-WMSDs) and latency of effect].
  • BACKGROUND: Trends in work-related upper limb musculoskeletal disorders appear to be in constant increase in industrialized countries.
  • OBJECTIVE: The aim of this study was to investigate the temporal relationship between the beginning of occupational exposure to repetitive movements and exertions of upper limbs, assessed through the OCRA index, and the manifestation of the disorders.
  • METHODS: Clinical and questionnaire information about 557 cases of UL-WMSDs in the upholstered furniture industry were analyzed in order to investigate the mean latency period of the disorders and to verify to what extent different levels of exposure influence the latency time.
  • RESULTS AND CONCLUSIONS: The latency of UL-WMSDs is influenced by the level of exposure to risk, measured by means of the OCRA index.
  • Shorter latency times were found for wrist/hand tendonitis, with a mean latency time of 5.4 years and with a greater sensitivity to the level of exposure assessed with the OCRA index value.
  • This might support a sort of predictive value with reference to other UL-WMSDs with longer latency.
  • Probably a latency period of 12 years may be suggested as the cut-off limit to assess a causal relationship between tendon or canalicular WMISDs and occupational exposure to repetitive movements and exertions of upper limbs.
  • [MeSH-major] Arm Injuries / epidemiology. Cumulative Trauma Disorders / epidemiology. Occupational Diseases / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Arm Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18828534.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Loviscek LF, Yun JH, Park YS, Chiari A, Grillo C, Cenoz MC: [Leiomyoma of the oesophagus]. Cir Esp; 2009 Mar;85(3):147-51
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leiomyoma of the oesophagus].
  • [Transliterated title] Leiomioma de esófago.
  • INTRODUCTION: Oesophageal leiomyoma is a rare tumour.
  • CONCLUSIONS: Enucleation of oesophageal leiomyomas by video-thoracoscopy is safe, well tolerated, and there is a rapid recovery, and is the procedure of choice for this benign tumour.
  • [MeSH-major] Esophageal Neoplasms. Leiomyoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309602.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


59. Krishnamoorthy K, Mathew T, Ramachandran G: Upper limits for exceedance probabilities under the one-way random effects model. Ann Occup Hyg; 2007 Jun;51(4):397-406
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limits for exceedance probabilities under the one-way random effects model.
  • In this article, we propose statistical methods for setting upper limits on (i) the probability that the mean exposure of an individual worker exceeds the occupational exposure limit (OEL) and (ii) the probability that the exposure of a worker exceeds the OEL.
  • The proposed method for (i) is obtained using the generalized variable approach, and the one for (ii) is based on an approximate method for constructing one-sided tolerance limits in the one-way random effects model.
  • Even though tolerance limits can be used to assess the proportion of exposure measurements exceeding the OEL, the upper limits on these probabilities are more informative than tolerance limits.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519274.001).
  • [ISSN] 0003-4878
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Grant] United States / NIOSH CDC HHS / OH / R01-OH03628-01A1
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational
  •  go-up   go-down


60. Sánchez Merino JM, Guillán Maquieira C, Galán Ramos J, Valerdiz Casasola S, Parra Muntaner L, Gómez Cisneros SC, García Alonso J: [Bladder leiomyoma. A case report and literature review]. Arch Esp Urol; 2005 Nov;58(9):950-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder leiomyoma. A case report and literature review].
  • [Transliterated title] Leiomioma vesical.
  • OBJECTIVES: To report a new case of bladder leiomyoma.
  • METHODS: A 20 mm tumor of the right lateral wall of the bladder was incidentally found in a pelvic ultrasound study of a 29-year-old female.
  • Cystoscopy showed a right lateral wall tumor with normal mucosal cover.
  • RESULTS: With the working diagnosis of bladder leiomyoma, transurethral resection of the bladder tumor was performed, and pathology confirmed the diagnosis.
  • Postoperatively, the patient developed a calcareous plaque on the resection area which was treated by transurethral resection of the plaque and leiomyoma remainders and subsequence urine acidification.
  • CONCLUSION: Although it is a rare tumor, in certain circumstances it is possible to establish the working preoperative diagnosis with a high index of suspicion.
  • On the other hand, due to the benign character of the process, conservative surgery (transurethral resection in this case) offers excellent results.
  • [MeSH-major] Leiomyoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430044.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 25
  •  go-up   go-down


61. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T: Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology; 2010 Jun;151(6):2433-42
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone is essential for maintenance and growth of uterine leiomyoma.
  • Uterine leiomyomata (ULs) represent the most common tumor in women and can cause abnormal uterine bleeding, large pelvic masses, and recurrent pregnancy loss.
  • Although the dependency of UL growth on ovarian steroids is well established, the relative contributions of 17beta-estradiol and progesterone are yet to be clarified.
  • Conventionally, estradiol has been considered the primary stimulus for UL growth, and studies with cell culture and animal models support this concept.
  • In contrast, no research model has clearly demonstrated a requirement of progesterone in UL growth despite accumulating clinical evidence for the essential role of progesterone in this tumor.
  • To elucidate the functions of ovarian steroids in UL, we established a xenograft model reflecting characteristics of these tumors by grafting human UL tissue beneath the renal capsule of immunodeficient mice.
  • Leiomyoma xenografts increased in size in response to estradiol plus progesterone through cell proliferation and volume increase in cellular and extracellular components.
  • Furthermore, the volume of established UL xenografts decreased significantly after progesterone withdrawal.
  • Surprisingly, treatment with estradiol alone neither increased nor maintained the tumor size.
  • Although not mitogenic by itself, estradiol induced expression of progesterone receptor and supported progesterone action on leiomyoma xenografts.
  • Taken together, our findings define that volume maintenance and growth of human UL are progesterone dependent.

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1296-304 [16464945.001]
  • [Cites] Epidemiology. 2003 Mar;14(2):247-50 [12606893.001]
  • [Cites] J Minim Invasive Gynecol. 2006 Sep-Oct;13(5):386-90 [16962519.001]
  • [Cites] J Reprod Med. 2006 Sep;51(9):671-4 [17039693.001]
  • [Cites] Obstet Gynecol. 2006 Dec;108(6):1381-7 [17138770.001]
  • [Cites] Fertil Steril. 2007 Apr;87(4):725-36 [17430732.001]
  • [Cites] Hum Reprod. 2007 Jun;22(6):1696-704 [17339234.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(4):CD005287 [17943846.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4459-66 [17785366.001]
  • [Cites] Med Sci Monit. 2008 Jan;14(1):CR24-31 [18160941.001]
  • [Cites] Gynecol Endocrinol. 2008 May;24(5):250-6 [18569028.001]
  • [Cites] Hum Reprod. 2008 Aug;23(8):1873-83 [18492705.001]
  • [Cites] Am J Obstet Gynecol. 2008 Aug;199(2):156.e1-8 [18468574.001]
  • [Cites] Obstet Gynecol. 2008 Nov;112(5):1029-36 [18978102.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Dec;93(12):4664-71 [18765509.001]
  • [Cites] Hum Reprod. 2009 Aug;24(8):1870-9 [19389793.001]
  • [Cites] Cancer Lett. 2005 Apr 18;221(1):49-53 [15797626.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Jun;278(6):R1415-23 [10848506.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3852-61 [11014242.001]
  • [Cites] Biol Reprod. 2000 Nov;63(5):1322-30 [11058535.001]
  • [Cites] Biol Reprod. 2001 Jan;64(1):272-83 [11133684.001]
  • [Cites] Am J Epidemiol. 2001 Jan 1;153(1):20-6 [11159141.001]
  • [Cites] J Cell Physiol. 2001 Mar;186(3):414-24 [11169981.001]
  • [Cites] J Immunol. 2001 Feb 1;166(3):2080-9 [11160259.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):793-805 [11715046.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1708-12 [11721053.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):2049-52 [11751438.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Mar;228(3):308-14 [12626776.001]
  • [Cites] Fertil Steril. 2003 Jun;79(6):1380-9 [12798886.001]
  • [Cites] Hum Reprod. 2004 Apr;19(4):815-21 [15033949.001]
  • [Cites] Hum Reprod Update. 2004 May-Jun;10(3):207-20 [15140868.001]
  • [Cites] Obstet Gynecol. 1985 Jul;66(1):36-41 [3892387.001]
  • [Cites] Int J Gynecol Pathol. 1985;4(2):89-96 [3926664.001]
  • [Cites] Am J Obstet Gynecol. 1989 Mar;160(3):637-41 [2929683.001]
  • [Cites] EMBO J. 1990 May;9(5):1603-14 [2328727.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2051-6 [1327484.001]
  • [Cites] Gynecol Obstet Invest. 1992;34(2):111-4 [1356890.001]
  • [Cites] J Ultrasound Med. 1992 Oct;11(10):511-5 [1404579.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):900-6 [8077380.001]
  • [Cites] Biol Reprod. 1995 Apr;52(4):824-32 [7780004.001]
  • [Cites] Endocrinology. 1995 Nov;136(11):4996-5003 [7588234.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2246-53 [8641172.001]
  • [Cites] Epidemiology. 1996 Jul;7(4):440-2 [8793374.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] Mol Hum Reprod. 1996 Nov;2(11):823-8 [9237221.001]
  • [Cites] J Soc Gynecol Investig. 1995 May-Jun;2(3):542-51 [9420857.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):2192-8 [9626159.001]
  • [Cites] Fertil Steril. 1998 Sep;70(3):432-9 [9757871.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jan;192(1):323-32 [15672043.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] J Minim Invasive Gynecol. 2005 May-Jun;12(3):227-33 [15922980.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6450-8 [16024650.001]
  • [Cites] Differentiation. 2005 Jul;73(6):313-22 [16138832.001]
  • [Cites] Lab Invest. 2005 Nov;85(11):1392-404 [16155594.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jan;188(1):100-7 [12548202.001]
  • [Cites] Mol Hum Reprod. 2006 Mar;12(3):187-207 [16524927.001]
  • (PMID = 20375184.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD057877; United States / NICHD NIH HHS / HD / R01 HD064402; United States / NICHD NIH HHS / HD / HD057877
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2875812
  •  go-up   go-down


62. Cojocaru E: Dispersion analysis of hollow-core modes in ultralarge-bandwidth all-silica Bragg fibers with nanosupports. Appl Opt; 2006 Mar 20;45(9):2039-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dispersion analysis of hollow-core modes in ultralarge-bandwidth all-silica Bragg fibers with nanosupports.
  • Anomalies in the group-velocity dispersion are evidenced at long wavelengths, toward the upper limit of the bandgap.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579575.001).
  • [ISSN] 0003-6935
  • [Journal-full-title] Applied optics
  • [ISO-abbreviation] Appl Opt
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Christacos NC, Quade BJ, Dal Cin P, Morton CC: Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer; 2006 Mar;45(3):304-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features.
  • Cytogenetic analysis of uterine leiomyomata (UL) shows that about 40% of these benign tumors have simple, clonal chromosomal rearrangements.
  • Several variants of benign uterine smooth-muscle tumors are defined by histologic phenotypes intermediate between typical UL and LMS, and currently, little is known about their cytogenetic and molecular genetic features.
  • From a subset of more than 800 karyotyped ULs, we identified a group of nine cases exhibiting near-diploid karyotypes with loss of almost the entire short (p) arm of chromosome 1 [i.e., del(1)(p11p36)].
  • Of eight UL for which the histologic diagnosis was known, four were diagnosed as cellular UL; one displayed both hypercellularity and nuclear atypia.
  • Loss of heterozygosity (LOH) analysis for chromosomal regions 1p36.23 and 1p21.1 demonstrated allelic loss for either a portion or the majority of 1p in 5 of 10 additional archival UL diagnosed with either cellular or atypical histology.
  • RNA from two UL with loss of 1p was profiled using Affymetrix GeneChips, and those profiles were compared to our previously reported smooth-muscle tumor expression profile.
  • The transcriptional profiles of tumors with 1p deletion were more similar to those of leiomyosarcoma than to profiles of myometrium and UL, as determined by hierarchical cluster analysis.
  • Comparison of the transcriptional profiles for UL with and without 1p-- revealed 53 genes with differential regulation.
  • Loss of 1p appears to define a subgroup of UL distinct from those previously recognized.
  • The similarity between the transcriptional profiles of LMS and UL with 1p-- suggests the possibility of a common pathogenetic mechanism.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Leiomyosarcoma / genetics. Myometrium / metabolism. Uterine Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320247.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA78895; United States / NIGMS NIH HHS / GM / T32 GM0077
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Candela G, Varriale S, Di Libero L, Maschio A, Manetta F, Giordano M, Nunziata A, Santini L: [Thoracotomy enucleation of a giant leiomyoma of the upper oesophagus. Case report and review of the literature]. Chir Ital; 2007 Jan-Feb;59(1):123-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracotomy enucleation of a giant leiomyoma of the upper oesophagus. Case report and review of the literature].
  • [Transliterated title] Enucleazione toracotomica di un leiomioma gigante dell'esofago toracico superiore. Caso clinico e revisione della letteratura.
  • The authors report on a case of fibro-leiomyoma of the upper oesophagus.
  • Computed tomography and magnetic resonance of the thorax revealed a solid voluminous formation at the level of the posterior upper mediastinum.
  • The US-endoscopy showed that this was a tumour originating from the esophageal wall with macroscopic characteristics of benignity, suggestive of a leiomyoma.
  • The patient was treated by thoracotomy enucleation of the large tumour after sectioning the azygous vein on the same side as the lesion.
  • Histological examination of the surgical resection confirmed that the tumour was a fibro-leiomyoma of the esophagus with a conspicuous vascular component and an interstitial inflammatory focus.
  • [MeSH-major] Esophageal Neoplasms / surgery. Leiomyoma / surgery. Thoracoscopy. Thoracotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361941.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 17
  •  go-up   go-down


65. Hodge JC, Quade BJ, Rubin MA, Stewart EA, Dal Cin P, Morton CC: Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. Am J Pathol; 2008 May;172(5):1403-10
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids.
  • The plexiform variant of uterine leiomyomata (UL) is named for its ribbons or nests of smooth muscle cells that have a rounded, epithelioid shape caused by their entrapment in abundant extracellular matrix.
  • Plexiform UL are currently classified as epithelioid smooth muscle tumors alongside the less predictable, "true" epithelioid tumors (ie, leiomyoblastomas).
  • Karyotypes of six plexiform UL cases were studied, and their abnormalities were found to differ from those of leiomyoblastomas.
  • Analyses using real-time polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization demonstrated elevated mRNA and protein levels of the architectural factor HMGA2 and, in some cases, increased DNA copy number.
  • Four of these plexiform UL were profiled with Affymetrix human U133 plus 2.0 expression arrays.
  • Cluster analysis using genes previously shown to discriminate benign and malignant uterine smooth muscle tissues revealed that the plexiform tumors form an isolated group in the benign branch.
  • This is in contrast to an earlier finding in which another variant, cellular UL characterized by loss of a portion of the short arm of chromosome 1, clustered with malignant leiomyosarcomas.
  • These results provide additional evidence of genetic heterogeneity underlying UL of various histological types.
  • We further suggest that plexiform UL should be classified among tumors with extensive hyalinization rather than with "true" epithelioid smooth muscle neoplasms.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Nov;155(5):1535-42 [10550310.001]
  • [Cites] Obstet Gynecol. 2006 Oct;108(4):930-7 [17012456.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):953-8 [11237021.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):63-81 [11602345.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):351-6 [11904348.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):205-6 [12508249.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):51-4 [12519945.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Sep;38(1):68-79 [12874787.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):97-108 [15101043.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5570-7 [15313893.001]
  • [Cites] Cancer. 1972 Feb;29(2):305-11 [4335235.001]
  • [Cites] Arch Pathol. 1974 May;97(5):263-8 [4131960.001]
  • [Cites] Cancer. 1976 Apr;37(4):1853-65 [56982.001]
  • [Cites] Arch Pathol Lab Med. 1978 Sep;102(9):477-80 [581153.001]
  • [Cites] Cancer. 1979 Nov;44(5):1707-14 [498042.001]
  • [Cites] Am J Surg Pathol. 1980 Feb;4(1):59-74 [7361995.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(2):124-34 [6092289.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1245-50 [17767157.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2239-47 [3179938.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):435-8 [2220671.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):3-13 [2278965.001]
  • [Cites] Obstet Gynecol. 1991 Jun;77(6):923-6 [2030869.001]
  • [Cites] Obstet Gynecol. 1992 Aug;80(2):209-17 [1635734.001]
  • [Cites] Arch Pathol Lab Med. 1992 Nov;116(11):1189-91 [1444750.001]
  • [Cites] Arch Pathol Lab Med. 1993 Dec;117(12):1255-6 [8250699.001]
  • [Cites] Science. 1994 May 20;264(5162):1100-1 [8178167.001]
  • [Cites] Trends Genet. 1994 Mar;10(3):94-100 [8178371.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Oct;77(1):65-8 [7923086.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Apr;80(2):103-6 [7736423.001]
  • [Cites] Nat Genet. 1995 Aug;10(4):436-44 [7670494.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):1-6 [8889500.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):270-5 [8910640.001]
  • [Cites] MMWR CDC Surveill Summ. 1997 Aug 8;46(4):1-15 [9259214.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5237-46 [10409715.001]
  • [Cites] Pathology. 1999 Aug;31(3):292-4 [10503280.001]
  • [Cites] Am J Hum Genet. 2005 Feb;76(2):340-8 [15593017.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):304-12 [16320247.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):59-68 [16533427.001]
  • [Cites] Am J Obstet Gynecol. 2006 Oct;195(4):955-64 [16723104.001]
  • [Cites] Obstet Gynecol. 2000 May;95(5):764-9 [10775744.001]
  • (PMID = 18403592.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01HD046226; United States / NCI NIH HHS / CA / R01 CA078895; United States / NCI NIH HHS / CA / R01CA78895; United States / NIGMS NIH HHS / GM / T32GM007748; United States / NIGMS NIH HHS / GM / T32 GM007748; United States / NICHD NIH HHS / HD / R01 HD046226
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein
  • [Other-IDs] NLM/ PMC2329848
  •  go-up   go-down


66. Nixon CA, Achterberg RK, Teanby NA, Irwin PG, Flaud JM, Kleiner I, Dehayem-Kamadjeu A, Brown LR, Sams RL, Bézard B, Coustenis A, Ansty TM, Mamoutkine A, Vinatier S, Bjoraker GL, Jennings DE, Romani PN, Flasar FM: Upper limits for undetected trace species in the stratosphere of Titan. Faraday Discuss; 2010;147:65-81; discussion 83-102
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limits for undetected trace species in the stratosphere of Titan.
  • We find non-detections in all cases, but derive upper limits on the abundances from low-noise observations at 25 degrees S and 75 degrees N.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302543.001).
  • [ISSN] 1359-6640
  • [Journal-full-title] Faraday discussions
  • [ISO-abbreviation] Faraday Discuss.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Ban JH, Chang J, Im GJ, Jung HH: Proteomic analysis of the rat vestibular nucleus complex following unilateral labyrinthectomy. Acta Otolaryngol; 2009 Aug;129(8):846-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of the rat vestibular nucleus complex following unilateral labyrinthectomy.
  • OBJECTIVE: The purpose of this study was to identify the proteins expressed in vestibular nucleus complexes (VNCs) using proteomics following unilateral labyrinthectomy.
  • MATERIALS AND METHODS: Proteomic analysis was performed in VNCs of rats at 6 h, 72 h, and 7 days following unilateral labyrinthectomy in comparison to normal VNC.
  • Among these, 14 proteins were highly expressed in normal VNCs and 8 were newly expressed following labyrinthectomy.
  • Among these 14 normal proteins, 9 were consistently expressed in both normal and labyrinthectomized VCNs, while 5 were down-regulated following labyrinthectomy.
  • Eight were newly expressed following labyrinthectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941951.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Kwack SJ, Kim KB, Lee BM: Estimation of tolerable upper intake level (UL) of active aloe. J Toxicol Environ Health A; 2009;72(21-22):1455-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of tolerable upper intake level (UL) of active aloe.
  • Therefore, this study was conducted to investigate a tolerable upper intake level (UL) of active aloe or a maximal allowable daily intake (ADImax) of active aloe based on 4-wk oral toxicity investigation in ICR mice.
  • An active aloe was daily administered to male and female ICR mice for 4 wk at different dose levels (0, 120, 600, 3000, or 15,000 mg/kg body weight [bw]).
  • All animals were sacrificed at the end of the experiment and changes of body weight, food consumption, organ weights, and hematological and biochemical parameters were recorded.
  • In females, a dose-dependent quantitative decrease in albumin (ALB) levels was observed, but it was not significant, due to wide interindividual variations.
  • A significant decrease in male kidney weight was observed from the 120-mg/kg to the 15,000-mg/kg bw treatment groups, and blood urea nitrogen (BUN) levels were also quantitatively lower.
  • A dose-dependent reduction in the body weight of females was also observed, which might be related to less food consumption.
  • Based on the reduced kidney weights in males, the lowest-observed-adverse-effect level (LOAEL) of an active aloe was estimated to be 120 mg/kg bw in male ICR mice, and the UL or ADImax was 0.4 mg/kg bw/d [(120 mg/kg bw/d)/(100 for safety factor) x (3 for modifying factor)], or 24 mg for a 60-kg adult (24 mg x 200 = 4.8 g of aloe gel/d/adult), assuming that consumers utilize active aloe for a month.
  • [MeSH-minor] Animals. Body Weight / drug effects. Dose-Response Relationship, Drug. Female. Heart / drug effects. Kidney / drug effects. Liver / drug effects. Lung / drug effects. Male. Mice. Sex Characteristics. Spleen / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077218.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Zou Y, Kong W: [Expression change of Muscarinic receptor subunits in rat flocculus following unilateral labyrinthectomy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Oct;22(19):896-8, 903

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression change of Muscarinic receptor subunits in rat flocculus following unilateral labyrinthectomy].
  • OBJECTIVE: To observe the expression of Muscarinic receptor M1, M3, M5 subunits in rat flocculus following left unilateral labyrinthectomy (UL).
  • METHOD: The RT-PCR was used to observe the expression of Muscarinic receptor M1, M3, M5 subunits post-unilateral labyrinthectomy and investigate its effect on vestibular compensation.
  • RESULT: Muscarinic receptor M1, M3, M5 subunits were induced decrease in both side flocculus after unilateral labyrinthectomy.
  • The expression was the least in the 1 d flocculus of following UL.
  • The expression is rising from the 3-7 d flocculus of following UL.
  • No difference was observed in the 7 d and sham operation flocculus following UL.
  • CONCLUSION: Muscarinic receptor M1, M3, M5 subunits were induced decrease in the flocculus after unilateral labyrinthectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160866.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptor, Muscarinic M1; 0 / Receptor, Muscarinic M3; 0 / Receptor, Muscarinic M5
  •  go-up   go-down


70. Wühr M, Chen Y, Dumont S, Groen AC, Needleman DJ, Salic A, Mitchison TJ: Evidence for an upper limit to mitotic spindle length. Curr Biol; 2008 Aug 26;18(16):1256-61
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for an upper limit to mitotic spindle length.
  • Here, we show that spindle length increases with cell length in small cells, but in very large cells spindle length approaches an upper limit of approximately 60 microm.
  • Further evidence for an upper limit to spindle length comes from an embryonic extract system that recapitulates mitotic spindle assembly in a test tube.
  • We conclude that early mitotic spindle length in Xenopus laevis is uncoupled from cell length, reaching an upper bound determined by mechanisms that are intrinsic to the spindle.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2005 Jun;16(6):3064-76 [15788560.001]
  • [Cites] Mech Dev. 2005 Mar;122(3):273-87 [15763208.001]
  • [Cites] Methods Mol Biol. 2006;322:69-86 [16739717.001]
  • [Cites] Development. 2006 Oct;133(19):3883-93 [16943269.001]
  • [Cites] J Cell Biol. 2007 Mar 12;176(6):765-70 [17339377.001]
  • [Cites] Curr Biol. 2007 Mar 20;17(6):488-98 [17346968.001]
  • [Cites] Nature. 2007 May 24;447(7143):493-6 [17495931.001]
  • [Cites] Curr Biol. 2007 Aug 21;17(16):1373-83 [17702580.001]
  • [Cites] Mol Reprod Dev. 2000 Jan;55(1):75-82 [10602276.001]
  • [Cites] Curr Biol. 2000 Oct 19;10(20):1303-6 [11069114.001]
  • [Cites] Cell. 2001 Jun 1;105(5):645-55 [11389834.001]
  • [Cites] Dev Dyn. 2002 Dec;225(4):522-35 [12454928.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:677-93 [15473856.001]
  • [Cites] J Cell Biol. 1985 Jan;100(1):1-7 [4038398.001]
  • [Cites] J Cell Biol. 1985 Aug;101(2):518-23 [3926780.001]
  • [Cites] Nature. 1989 May 25;339(6222):275-80 [2566917.001]
  • [Cites] Exp Cell Res. 1989 Nov;185(1):271-6 [2509228.001]
  • [Cites] Nature. 1989 Nov 30;342(6249):512-8 [2531292.001]
  • [Cites] Ann N Y Acad Sci. 1990;582:40-9 [2356982.001]
  • [Cites] J Cell Biol. 1991 Mar;112(5):925-40 [1999463.001]
  • [Cites] Zygote. 1995 Feb;3(1):17-26 [7613871.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):420-5 [8684481.001]
  • [Cites] Curr Top Dev Biol. 1995;31:383-431 [8746671.001]
  • [Cites] Nature. 1997 Oct 9;389(6651):640-3 [9335509.001]
  • [Cites] Methods Cell Biol. 1999;61:385-412 [9891325.001]
  • [Cites] J Embryol Exp Morphol. 1963 Mar;11:267-78 [13952338.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1213-8 [16554437.001]
  • (PMID = 18718761.001).
  • [ISSN] 0960-9822
  • [Journal-full-title] Current biology : CB
  • [ISO-abbreviation] Curr. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM068763; United States / NIGMS NIH HHS / GM / P50 GM068763-1; United States / NIGMS NIH HHS / GM / R01 GM039565; United States / NIGMS NIH HHS / GM / R37 GM039565; United States / NIGMS NIH HHS / GM / GM39565; United States / NIGMS NIH HHS / GM / GM039565-19; United States / NIGMS NIH HHS / GM / R37 GM039565-19
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS67567; NLM/ PMC2561182
  •  go-up   go-down


71. Vinh-Thang H, Huang Q, Ungureanu A, Eić M, Trong-On D, Kaliaguine S: Structural and diffusion characterizations of steam-stable mesostructured zeolitic UL-ZSM-5 materials. Langmuir; 2006 May 9;22(10):4777-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and diffusion characterizations of steam-stable mesostructured zeolitic UL-ZSM-5 materials.
  • A series of mesoporous UL-ZSM-5 materials (Si/Al = 50) with different micro- and mesoporosity as well as crystallinity was prepared following the procedure proposed in one of our recent studies (Trong-On, D.
  • UL-ZSM-5 materials were shown to be highly hydrothermally stable.
  • The diffusion of two C7 hydrocarbons, i.e., n-heptane and toluene, in four UL-ZSM-5 materials with different microporosities, related acidities, and crystallinities were investigated using the zero-length column (ZLC) method.
  • The transport of n-heptane in UL-ZSM-5 materials was found to be mainly controlled by mesopore diffusion in the main-channel structure, while that of toluene was dominated by the intrawall diffusion process.
  • Furthermore, the effect of hydrothermal treatment (20% steam at 800 degrees C for 24 h) on the diffusion of these two sorbates on UL-ZSM-5 materials was also evaluated.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649795.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, Reinhart K, Brunkhorst FM: Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica; 2008 Jan;93(1):137-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor.
  • A marked imbalance between ADAMTS13 activity and VWF antigen level was associated with the appearance of ultra-large VWF multimers in plasma, with organ dysfunction and lethality.
  • [MeSH-minor] Adult. Aged. Antigens / chemistry. Blood Platelets / metabolism. Female. Hemostasis. Humans. Male. Middle Aged. Sepsis / diagnosis. Thrombosis / blood. Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166799.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens; 0 / von Willebrand Factor; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAMTS13 protein, human
  •  go-up   go-down


73. Figer DF: An upper limit to the masses of stars. Nature; 2005 Mar 10;434(7030):192-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An upper limit to the masses of stars.
  • There is no accepted upper mass limit for stars.
  • The Arches cluster is ideal for investigating such limits, being large enough to expect stars at least as massive as approximately 500 solar masses (approximately 500 Mo; based on a typical mass function), and young enough for its most massive members to still be visible.
  • I conclude that this indicates a firm limit of 150 Mo for stars; the probability that the observations are consistent with there being no upper limit is 10(-8).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nature. 2005 Mar 10;434(7030):148-9 [15758978.001]
  • (PMID = 15758993.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Bonduki CE, Dornelas Junior Gde O, Bernardo A, Simões Mde J, Castro Rde A, Gomes MT, Girão MJ: [Collagen histomorphometric evaluation in uterin tissue samples before and after treatment of uterine fibroids with arterial embolization]. Rev Bras Ginecol Obstet; 2009 Dec;31(12):598-603
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Collagen histomorphometric evaluation in uterin tissue samples before and after treatment of uterine fibroids with arterial embolization].
  • [Transliterated title] Avaliação da proporção de colágeno no tecido uterino antes e após tratamento do leiomioma uterino pela embolização arterial.
  • PURPOSE: To analyze histomorphometric consequences of the uterine arteries embolization (UAE) in the uterine tissue, especially by collagen tissue quantification through uterine biopsy, before and after treatment of uterine leiomyoma.
  • Uterine biopsy was performed in the secretory phase of the menstrual cycle, before and three months after the procedure, to evaluate the collagen.
  • RESULTS: The presence of smooth muscle cells was observed in the biopsies performed before the treatment, surrounded by a rich network of collagen fibers, which are part of the tumor, blood vessels and fibroblast nuclei.
  • CONCLUSION: The quantitative and qualitative collagen reduction clearly shows that the proposed treatment is efficient in reducing the tumoral mass, composed mainly by collagen fibers intermingled with neoplasic smooth muscle cells.
  • [MeSH-major] Collagen / analysis. Embolization, Therapeutic. Leiomyoma / therapy. Uterine Neoplasms / therapy. Uterus / chemistry. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20101374.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


75. Wang Y, Liu YQ, Li XL, Cao LC, Wei DC, Zhang HL, Shi DC, Yu G: Large-scale growth and characteristics of N-doped carbon nanotubes with ultra-large cavity. J Nanosci Nanotechnol; 2009 Feb;9(2):1076-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-scale growth and characteristics of N-doped carbon nanotubes with ultra-large cavity.
  • N-doped carbon nanotubes (CNTs) with ultra-large cavity have been synthesized by using a mixture of ZnO and graphite as catalyst in the floating catalyst method.
  • Moreover, electronic properties analysis reveals that the N-doped CNTs with ultra-large cavity have a reduced room temperature resistance compared with those of the common N-doped CNTs, which give an experimental prove for the previous theoretical predictions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19441459.001).
  • [ISSN] 1533-4880
  • [Journal-full-title] Journal of nanoscience and nanotechnology
  • [ISO-abbreviation] J Nanosci Nanotechnol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Gézsi A, Budde U, Deák I, Nagy E, Mohl A, Schlammadinger A, Boda Z, Masszi T, Sadler JE, Bodó I: Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza. J Thromb Haemost; 2010 Jun;8(6):1273-80
Genetic Alliance. consumer health - Von Willebrand Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.
  • BACKGROUND: von Willebrand disease (VWD) Vicenza is characterized by low plasma von Willebrand factor (VWF) levels, the presence of ultra-large (UL) VWF multimers and less prominent satellite bands on multimer gels, and the heterozygous amino acid substitution R1205H in the VWF gene.
  • Accelerated clearance is implicated as a cause of low VWF level.
  • OBJECTIVES: We addressed the question, whether the presence of ultra-large multimers is a cause, or a result of accelerated VWF clearance, or whether it is an unrelated phenomenon.
  • A mathematical model of the complex interplay of VWF synthesis, clearance and cleavage showed that decreasing VWF half-life to one-tenth of normal reproduced all features of VWD Vicenza including low VWF level, ultra-large multimers and a decrease of satellite band intensity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Haemost. 2000 Jan;83(1):136-40 [10669167.001]
  • [Cites] Blood. 2008 May 15;111(10):4979-85 [18344424.001]
  • [Cites] Thromb Haemost. 2000 Aug;84(2):350-1 [10959712.001]
  • [Cites] Blood. 2002 Jan 1;99(1):180-4 [11756169.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4243-4; author reply 4244 [12043692.001]
  • [Cites] J Thromb Haemost. 2003 Aug;1(8):1714-7 [12911582.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12102-9 [14613933.001]
  • [Cites] Mol Cell Biol. 1987 Jan;7(1):379-87 [3031469.001]
  • [Cites] Mol Cell Biol. 1987 Aug;7(8):2745-52 [3670292.001]
  • [Cites] Blood. 1988 Jan;71(1):65-70 [3257148.001]
  • [Cites] Eur J Haematol. 1988 Feb;40(2):163-7 [3126081.001]
  • [Cites] Thromb Res. 1990 Nov 1;60(3):201-12 [2084949.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6377-81 [1906179.001]
  • [Cites] J Biol Chem. 1992 Mar 5;267(7):4424-30 [1537829.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13406-14 [7539426.001]
  • [Cites] Thromb Res. 1997 Jul 1;87(1):57-64 [9253800.001]
  • [Cites] J Thromb Haemost. 2005 Oct;3(10):2228-37 [16194200.001]
  • [Cites] J Lab Clin Med. 2006 Feb;147(2):96-102 [16459168.001]
  • [Cites] J Thromb Haemost. 2006 Oct;4(10):2103-14 [16889557.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3344-51 [16835381.001]
  • [Cites] J Thromb Haemost. 2007 Jul;5(7):1353-60 [17425686.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3531-9 [18230755.001]
  • [CommentIn] J Thromb Haemost. 2010 Jun;8(6):1271-2 [20230424.001]
  • (PMID = 20088930.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL072917; United States / NHLBI NIH HHS / HL / R01 HL089746; United States / NHLBI NIH HHS / HL / HL72917
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / von Willebrand Factor
  • [Other-IDs] NLM/ NIHMS528246; NLM/ PMC3863617
  •  go-up   go-down


77. Yang H, Buguin A, Taulemesse JM, Kaneko K, Méry S, Bergeret A, Keller P: Micron-sized main-chain liquid crystalline elastomer actuators with ultralarge amplitude contractions. J Am Chem Soc; 2009 Oct 21;131(41):15000-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micron-sized main-chain liquid crystalline elastomer actuators with ultralarge amplitude contractions.
  • The individual pillars behave as microactuators, showing ultralarge and reversible contractions of around 300-400% at the nematic to isotropic phase transition.
  • The nematic main-chain LCE microactuators described here present contractions as large as the best macroscopic systems reported in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778041.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Elastomers
  •  go-up   go-down


78. Muller SD, Nakagawa T, de Beaulieu JL, Court-Picon M, Fauquette S, Genries A: [Palaeostructures of vegetation at the upper limit of forests in the inner French Alps]. C R Biol; 2006 Jul;329(7):502-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Palaeostructures of vegetation at the upper limit of forests in the inner French Alps].
  • [Transliterated title] Paléostructures de végétation à la limite supérieure des forêts dans les Alpes françaises internes.
  • The comparison of six pollen diagrams from French Alps allows us to reconstruct the past changes of vegetation structure at the upper limit of Subalpine range.
  • Southern Alps seem however to be characterised by higher altitudinal limits, as shown by the past development of fir forests at 2080 m a.s.l. in the Ubaye valley.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797456.001).
  • [ISSN] 1631-0691
  • [Journal-full-title] Comptes rendus biologies
  • [ISO-abbreviation] C. R. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


79. Ashton JC, Little E, Muir M, Smith PF, Darlington CL: Mitochondrial ultrastructure and apoptotic protein expression in the vestibular nucleus complex following unilateral labyrinthectomy. Brain Res; 2005 Sep 7;1055(1-2):165-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial ultrastructure and apoptotic protein expression in the vestibular nucleus complex following unilateral labyrinthectomy.
  • We tested this using unilateral labyrinthectomy (UL) as a model for the effects of vestibular damage on the VNC and used Western blotting and electron microscopy to analyze mitochondria.
  • In rats receiving UL we did not find any changes in mitochondrial ultrastructure in the medial vestibular nucleus following UL, and there was no change in the expression or activation of the apoptosis effector caspase-3 in the whole VNC following UL.
  • However, we did detect a small but statistically significant upregulation of the anti-apoptotic protein Bcl-2 in the contralateral VNC at 10 h post-UL.
  • [MeSH-major] Apoptosis / physiology. Gene Expression Regulation / physiology. Labyrinth Diseases / metabolism. Mitochondria / ultrastructure. Neurons / metabolism. Vestibular Nuclei / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098486.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


80. Fishbane S: Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial; 2008 May-Jun;21(3):217-20
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines.
  • Therefore, international treatment guidelines generally recommend that intravenous (i.v.) iron be discontinued when serum ferritin is >500-1,000 ng/ml.
  • In the current review, relevant issues that inform decisions as to what levels of serum ferritin should be used as the upper limit for treatment are considered.
  • Instead, clinical judgment is critical to properly weigh risks and benefits of i.v. iron treatment, and to determine whether iron treatment is appropriate for a given patient with higher levels of iron tests.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Iron.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248518.001).
  • [ISSN] 0894-0959
  • [Journal-full-title] Seminars in dialysis
  • [ISO-abbreviation] Semin Dial
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 11096-26-7 / Erythropoietin; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  • [Number-of-references] 37
  •  go-up   go-down


81. Hodge JC, T Cuenco K, Huyck KL, Somasundaram P, Panhuysen CI, Stewart EA, Morton CC: Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet; 2009 Apr;125(3):257-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele.
  • Uterine leiomyomata (UL) are the most common female pelvic tumors and the primary indication for hysterectomy in the United States.
  • We assessed genetic liability for UL by a known embryonic proliferation modulator, HMGA2, in 248 families ascertained through medical record-confirmed affected sister-pairs.
  • Using a (TC)( n ) repeat in the 5' UTR and 17 SNPs spanning HMGA2, permutation-based association tests identified a significant increase in transmission of a single TC repeat allele (TC227) with UL (allele-specific P = 0.00005, multiple testing corrected min-P = 0.0049).
  • The hypothesis that TC227 is a pathogenic variant is supported by a trend towards higher HMGA2 expression in TC227 allele-positive compared with non-TC227 UL tissue as well as by absence of culpable exonic sequence variants.
  • Diminished stature and elevated risk of UL development have both been correlated with an earlier age of menarche, which may be the biological mechanism for TC227 effects as a tendency of women with TC227 to have an earlier onset of menarche was identified in our study population.
  • These results indicate HMGA2 has a role in two growth-related phenotypes, UL predisposition and height, of which the former may affect future medical management decisions for many women.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):350-7 [9824208.001]
  • [Cites] Fertil Steril. 1998 Sep;70(3):432-9 [9757871.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):316-22 [10398424.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):70-4 [10428474.001]
  • [Cites] Am J Epidemiol. 2005 Oct 1;162(7):623-32 [16107566.001]
  • [Cites] Obstet Gynecol. 2006 Apr;107(4):917-21 [16582132.001]
  • [Cites] Am J Obstet Gynecol. 2006 Oct;195(4):955-64 [16723104.001]
  • [Cites] Obstet Gynecol. 2006 Oct;108(4):930-7 [17012456.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e97 [17559308.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1245-50 [17767157.001]
  • [Cites] Am J Obstet Gynecol. 2008 Feb;198(2):168.e1-9 [18226615.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):198-203 [18193045.001]
  • [Cites] Nat Genet. 2008 May;40(5):584-91 [18391950.001]
  • [Cites] Nat Genet. 2008 May;40(5):609-15 [18391951.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1535-42 [10550310.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):187-95 [10631150.001]
  • [Cites] Hum Hered. 2000 Jul-Aug;50(4):211-23 [10782012.001]
  • [Cites] Bioinformatics. 2000 Feb;16(2):182-3 [10842743.001]
  • [Cites] Maturitas. 2000 Nov 30;37(1):15-26 [11099869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92 [11248088.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3101-9 [11751692.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):756-60 [12569368.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Sep;38(1):68-79 [12874787.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5570-7 [15313893.001]
  • [Cites] Acta Derm Venereol. 1973;53(5):409-16 [4127477.001]
  • [Cites] Fertil Steril. 1981 Oct;36(4):433-45 [7026295.001]
  • [Cites] Genetika. 1989 Oct;25(10):1896-8 [2620816.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):435-8 [2220671.001]
  • [Cites] Obstet Gynecol. 1991 Jun;77(6):923-6 [2030869.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jul;167(1):82-8 [1442963.001]
  • [Cites] Nature. 1995 Aug 31;376(6543):771-4 [7651535.001]
  • [Cites] Hum Genet. 1997 Jan;99(1):103-5 [9003504.001]
  • [Cites] MMWR CDC Surveill Summ. 1997 Aug 8;46(4):1-15 [9259214.001]
  • [Cites] Hum Hered. 1997 Nov-Dec;47(6):342-50 [9391826.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):1875-80 [9626112.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jul 20;248(2):402-5 [9675149.001]
  • [Cites] J Med Genet. 1999 Apr;36(4):295-9 [10227396.001]
  • (PMID = 19132395.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD046226-03; United States / NCI NIH HHS / CA / CA078895-09; United States / NICHD NIH HHS / HD / HD046226-05; United States / NCI NIH HHS / CA / CA078895-08; United States / NIGMS NIH HHS / GM / GM007748-27; United States / NCI NIH HHS / CA / R01 CA078895-10; United States / NIGMS NIH HHS / GM / T32 GM007748-27; United States / NICHD NIH HHS / HD / R01HD046226; United States / NCI NIH HHS / CA / R01 CA078895-09; United States / NICHD NIH HHS / HD / R01 HD046226-01; United States / NICHD NIH HHS / HD / HD046226-01; United States / NIGMS NIH HHS / GM / GM007748-29; United States / NCI NIH HHS / CA / CA078895-10; United States / NICHD NIH HHS / HD / R01 HD046226-04; United States / NICHD NIH HHS / HD / R01 HD060530; United States / NIGMS NIH HHS / GM / T32 GM007748-29; United States / NCI NIH HHS / CA / R01 CA078895; United States / NICHD NIH HHS / HD / R01 HD046226-02; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R01CA78895; United States / NIGMS NIH HHS / GM / T32GM007748; United States / NCI NIH HHS / CA / R01 CA078895-08; United States / NIGMS NIH HHS / GM / T32 GM007748-31; United States / NIGMS NIH HHS / GM / GM007748-28; United States / NIGMS NIH HHS / GM / T32 GM007748-28; United States / NIGMS NIH HHS / GM / T32 GM007748; United States / NCI NIH HHS / CA / CA078895-07; United States / NICHD NIH HHS / HD / R01 HD046226-03; United States / NICHD NIH HHS / HD / HD046226-02; United States / NICHD NIH HHS / HD / R01 HD046226-05; United States / NICHD NIH HHS / HD / R01 HD046226; United States / NICHD NIH HHS / HD / HD046226-04; United States / NIGMS NIH HHS / GM / GM007748-31; United States / NCI NIH HHS / CA / R01 CA078895-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / HMGA2 Protein
  • [Other-IDs] NLM/ NIHMS179706; NLM/ PMC2839499
  •  go-up   go-down


82. Huyck KL, Panhuysen CI, Cuenco KT, Zhang J, Goldhammer H, Jones ES, Somasundaram P, Lynch AM, Harlow BL, Lee H, Stewart EA, Morton CC: The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol; 2008 Feb;198(2):168.e1-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters.
  • OBJECTIVE: The objective of the study was to identify risk factors for uterine leiomyomata (UL) in a racially diverse population of women with a family history of UL, and to evaluate their contribution to disease severity and age at diagnosis.
  • STUDY DESIGN: We collected and analyzed epidemiologic data from 285 sister pairs diagnosed with UL.
  • Risk factors for UL-related outcomes were compared among black (n = 73) and white (n = 212) sister pairs using univariate and multivariate regression models.
  • RESULTS: Black women reported an average age at diagnosis of 5.3 years younger (SE, 1.1; P < .001) and were more likely to report severe disease (odds ratio, 5.22; 95% confidence interval, 1.99-13.7, P < .001) than white women of similar socioeconomic status.
  • CONCLUSION: Self-reported race is a significant factor in the severity of UL among women with a family history of UL.
  • The affected sister-pair study design can address both epidemiological and genetic hypotheses about UL.
  • [MeSH-major] Ethnic Groups / statistics & numerical data. Leiomyoma / epidemiology. Leiomyoma / ethnology. Siblings. Uterine Neoplasms / epidemiology. Uterine Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynaecol Obstet. 1995 Nov;51(2):127-31 [8635633.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jul;167(1):82-8 [1442963.001]
  • [Cites] Int J Eat Disord. 1997 Sep;22(2):127-30 [9261649.001]
  • [Cites] Obstet Gynecol. 1997 Dec;90(6):967-73 [9397113.001]
  • [Cites] Hum Reprod. 2006 Jan;21(1):57-67 [16172143.001]
  • [Cites] Obstet Gynecol Clin North Am. 2006 Mar;33(1):1-11 [16504803.001]
  • [Cites] Obstet Gynecol Clin North Am. 2006 Mar;33(1):13-39 [16504804.001]
  • [Cites] Vital Health Stat 23. 2005 Dec;(25):1-160 [16532609.001]
  • [Cites] Am J Obstet Gynecol. 2006 Oct;195(4):955-64 [16723104.001]
  • [Cites] Obstet Gynecol. 2006 Oct;108(4):930-7 [17012456.001]
  • [Cites] Matern Child Health J. 2007 Mar;11(2):137-44 [17066316.001]
  • [Cites] J Reprod Med. 1996 Jul;41(7):483-90 [8829060.001]
  • [Cites] Environ Health Perspect. 2000 Oct;108 Suppl 5:821-7 [11035989.001]
  • [Cites] Maturitas. 2000 Nov 30;37(1):15-26 [11099869.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):293-8 [11214143.001]
  • [Cites] Clin Obstet Gynecol. 2001 Jun;44(2):335-49 [11344997.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1241-52 [12761039.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):1037-54 [12826476.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):183-90 [15334541.001]
  • [Cites] Genetika. 1989 Oct;25(10):1896-8 [2620816.001]
  • [CommentIn] Am J Obstet Gynecol. 2008 Dec;199(6):e12; author reply e12-3 [18691692.001]
  • (PMID = 18226615.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD046226-01; United States / NICHD NIH HHS / HD / R01 HD046226-05; United States / NICHD NIH HHS / HD / HD046226; United States / NICHD NIH HHS / HD / R01 HD046226-02; United States / NCI NIH HHS / CA / P30 CA06516; United States / NICHD NIH HHS / HD / R01 HD046226-04; United States / NCI NIH HHS / CA / P30 CA006516; United States / NICHD NIH HHS / HD / R01 HD046226-03; United States / NICHD NIH HHS / HD / R01 HD046226
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39975; NLM/ PMC2265083
  •  go-up   go-down


83. Swerdlow CD, Shehata M, Chen PS: Using the upper limit of vulnerability to assess defibrillation efficacy at implantation of ICDs. Pacing Clin Electrophysiol; 2007 Feb;30(2):258-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using the upper limit of vulnerability to assess defibrillation efficacy at implantation of ICDs.
  • The upper limit of vulnerability (ULV) is the weakest shock strength at or above which ventricular fibrillation (VF) is not induced when the shock is delivered during the vulnerable period.
  • Vulnerability testing can be applied at implantable cardioverter defibrillator (ICD) implant to confirm a clinically adequate defibrillation safety margin without inducing VF in 75%-95% of ICD recipients.
  • Programming first ICD shocks based on patient-specific measurements of ULV rather than programming routinely to maximum output shortens charge time and may reduce the probability of syncope as ICDs age and charge times increase.
  • [MeSH-major] Algorithms. Differential Threshold. Electric Countershock / methods. Therapy, Computer-Assisted / methods. Ventricular Fibrillation / diagnosis. Ventricular Fibrillation / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338725.001).
  • [ISSN] 0147-8389
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL78931; United States / NHLBI NIH HHS / HL / R01 HL71140; United States / NHLBI NIH HHS / HL / R01 HL78932
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


84. VanDerWal J, Shoo LP, Johnson CN, Williams SE: Abundance and the environmental niche: environmental suitability estimated from niche models predicts the upper limit of local abundance. Am Nat; 2009 Aug;174(2):282-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abundance and the environmental niche: environmental suitability estimated from niche models predicts the upper limit of local abundance.
  • Therefore, ES should predict the upper limit of abundance, and the observed relationship with ES should be wedge shaped.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519279.001).
  • [ISSN] 1537-5323
  • [Journal-full-title] The American naturalist
  • [ISO-abbreviation] Am. Nat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


85. Shehata M, Belk P, Kremers M, Saba S, Cao J, Swerdlow CD: Automatic determination of timing intervals for upper limit of vulnerability using ICD electrograms. Pacing Clin Electrophysiol; 2008 Jun;31(6):691-700
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automatic determination of timing intervals for upper limit of vulnerability using ICD electrograms.
  • BACKGROUND: Implantable cardioverter defibrillator (ICD) implant testing based on the upper limit of vulnerability, or vulnerability testing, permits assessment of defibrillation safety margins without inducing ventricular fibrillation (VF) in most patients.
  • Our goal was to develop and test an automated method to select these timing intervals using ICD intracardiac electrograms (EGMs).
  • METHODS: At ICD implant in 22 patients, we determined the range of the most vulnerable intervals by scanning the T wave with shocks.
  • CONCLUSIONS: An automated method based on ICD EGMs identifies the most vulnerable intervals with accuracy comparable to the operator-performed, clinical method based on the surface ECG.
  • This EGM method can be implemented efficiently in an ICD to automate vulnerability testing.
  • [MeSH-major] Defibrillators, Implantable. Diagnosis, Computer-Assisted / methods. Electrocardiography / methods. Heart Failure / diagnosis. Heart Failure / prevention & control. Therapy, Computer-Assisted / methods


86. Bowden W, Skorupski J, Kovanci E, Rajkovic A: Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays. Mol Hum Reprod; 2009 Sep;15(9):563-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays.
  • Uterine leiomyomas (ULs) are benign monoclonal tumors originating from myometrial tissue in the uterus.
  • Genetic pathways that lead to myometrial transformation into leiomyomas are largely unknown.
  • Approximately 40% of ULs are karyotypically abnormal by G-banding; however, the remaining 60% of leiomyomas do not contain cytogenetically visible genomic rearrangements.
  • In the current study, we employed a high resolution SNP microarray on 16 randomly selected ULs and normal myometrium samples to detect submicroscopic (<5 Mb) chromosomal aberrations.
  • The SNP array identified gene dosage changes in 56% of the fibroids (9/16), 25% of which (4/16) had aberrations >5 Mb, whereas 31% of which (5/16) contained only submicroscopic copy number changes (<5 Mb).
  • Novel submicroscopic aberrations on chromosomal segments 1q42.13, 11q13.1 and 13q12.13 and large, previously unreported deletions on 15q11.2-q23, 17p-q21.31 and 22q12.2-q12.3 were identified.
  • RHOU, MAP3K11 and WASF3 gene copy numbers were changed in the subset of leiomyomas with submicroscopic aberrations, and these genes have previously been implicated in tumorigenesis.
  • Our findings support the hypothesis that a significant fraction of ULs without visible cytogenetic changes harbor submicroscopic genomic rearrangements which may in turn contribute to transformation of normal myometrial tissue into leiomyomas.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):1-8 [10958933.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1752-6 [19240151.001]
  • [Cites] Int J Oncol. 2002 Apr;20(4):777-83 [11894124.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Sep;137(2):133-7 [12393284.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R145-52 [12915456.001]
  • [Cites] Int J Mol Med. 2004 Jan;13(1):13-6 [14654964.001]
  • [Cites] Fertil Steril. 1981 Oct;36(4):433-45 [7026295.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):435-8 [2220671.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Jun;53(2):199-203 [2065294.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):11-8 [1913597.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Sep;11(1):1-6 [7529041.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):156-60 [9218996.001]
  • [Cites] Mol Carcinog. 1997 Aug;19(4):273-9 [9290705.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Oct 1;98(1):69-74 [9309121.001]
  • [Cites] Hum Pathol. 1998 May;29(5):476-81 [9596271.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1350-6 [16949924.001]
  • [Cites] Am J Med Genet A. 2007 Apr 15;143A(8):824-9 [17366576.001]
  • [Cites] BMC Womens Health. 2007;7:5 [17407572.001]
  • [Cites] Genomics. 2007 May;89(5):647-53 [17276656.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Apr 15;174(2):116-20 [17452252.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2112-21 [17525277.001]
  • [Cites] PLoS Genet. 2008;4(7):e1000129 [18636107.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1199-203 [18776910.001]
  • [Cites] Genes Dev. 2001 Jul 15;15(14):1796-807 [11459829.001]
  • (PMID = 19567454.001).
  • [ISSN] 1460-2407
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD058125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2725754
  •  go-up   go-down


87. Wang Y, Crookes D, Diamond J, Hamilton P, Turner R: Segmentation of squamous epithelium from ultra-large cervical histological virtual slides. Conf Proc IEEE Eng Med Biol Soc; 2007;2007:775-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmentation of squamous epithelium from ultra-large cervical histological virtual slides.
  • Cervical virtual slides are ultra-large, can have size up to 120K x 80K pixels.
  • The block-based segmentation method uses robust texture feature vectors in combination with a Support Vector Machine (SVM) to perform classification.
  • Results demonstrate that, with typical virtual slides, classification accuracies of between 94.9% and 96.3% are achieved.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Epithelium / pathology. Image Processing, Computer-Assisted / methods. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18002071.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Resende PC, Resende P, Pardal M, Almeida S, Azeiteiro U: Use of biological indicators to assess water quality of the Ul River (Portugal). Environ Monit Assess; 2010 Nov;170(1-4):535-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of biological indicators to assess water quality of the Ul River (Portugal).
  • The aim of this work was to assess the water quality and ecological status of the Ul River in order to evaluate its ability for the establishment of a fluvial beach, using periphytic diatoms and macroinvertebrates as indicators.
  • Four sites were selected along the Ul River.
  • We concluded that epilithic diatoms and macroinvertebrates provided consistent information on water quality assessment and can be used as biological indicators of the water quality in Ul River.
  • [MeSH-major] Diatoms / classification. Environmental Monitoring / methods. Invertebrates / classification. Rivers / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Pollut. 2008 May;153(2):440-9 [17923178.001]
  • (PMID = 20039204.001).
  • [ISSN] 1573-2959
  • [Journal-full-title] Environmental monitoring and assessment
  • [ISO-abbreviation] Environ Monit Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Water Pollutants
  •  go-up   go-down


89. Ordulu Z, Dal Cin P, Chong WW, Choy KW, Lee C, Muto MG, Quade BJ, Morton CC: Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer; 2010 Dec;49(12):1152-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.
  • Disseminated peritoneal leiomyomatosis (DPL) is a rare condition characterized by scattered smooth muscle nodules over the peritoneal surfaces.
  • Herein, we report a case of DPL occurring 7 years after laparoscopic supracervical hysterectomy with morcellation for uterine leiomyomata (UL).
  • We analyzed both the original UL and the subsequent DPL by molecular cytogenetics to assess the role of chromosomal abnormalities in DPL pathobiology.
  • Interestingly, all of the chromosomal aberrations detected in this case of DPL, including r(1)(p34.3q41), del(3)(q23q26.33), and t(12;14)(q14.3;q24.1), are characteristic chromosomal abnormalities detected in UL.
  • Fluorescence in situ hybridization analysis of the initial UL confirmed an interstitial deletion spanning at least 3q24 and 3q25.1, suggesting that functional alteration of a potential gene in this chromosomal region may play a role in DPL development from UL.
  • With the increasing rate of hysterectomy through laparoscopic approach to UL, the unique complications of laparoscopy with morcellation, especially seeding and proliferation of tumor cells over abdominal organs and peritoneum, are becoming more significant and may necessitate review of current surgical protocols to prevent future seeding of the pelvic region with tumor particles.

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • [Cites] Fertil Steril. 1981 Oct;36(4):433-45 [7026295.001]
  • [Cites] Cancer Genet Cytogenet. 1988 May;32(1):25-31 [3355998.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):4092-7 [2354458.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):173-5 [2114697.001]
  • [Cites] Am J Obstet Gynecol. 1990 Aug;163(2):591-3 [2386147.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):435-8 [2220671.001]
  • [Cites] Hum Genet. 1990 Oct;85(6):605-11 [2227952.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):3-13 [2278965.001]
  • [Cites] Anticancer Res. 1991 Jan-Feb;11(1):33-9 [2018368.001]
  • [Cites] Obstet Gynecol. 1991 Jun;77(6):923-6 [2030869.001]
  • [Cites] Obstet Gynecol. 1992 Aug;80(2):209-17 [1635734.001]
  • [Cites] Am J Obstet Gynecol. 1992 Aug;167(2):515-6 [1497063.001]
  • [Cites] Gynecol Obstet Invest. 1992;33(4):246-8 [1505817.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):293-305 [8424462.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jan;13(1):1-9 [8112951.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Dec;43(3):330-1 [7907050.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):535-58 [8179071.001]
  • [Cites] Obstet Gynecol. 1994 Jun;83(6):1015-20 [8190416.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Sep;11(1):1-6 [7529041.001]
  • [Cites] Cardiovasc Surg. 1994 Oct;2(5):642-5 [7820530.001]
  • [Cites] Mod Pathol. 1995 Feb;8(2):183-6 [7777481.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):219-20 [7669743.001]
  • [Cites] South Med J. 1996 Mar;89(3):291-4 [8604458.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Nov;51(2):127-31 [8635633.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):1-6 [8889500.001]
  • [Cites] Obstet Gynecol. 1997 May;89(5 Pt 2):853-4 [9166349.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2153-66 [9176406.001]
  • [Cites] MMWR CDC Surveill Summ. 1997 Aug 8;46(4):1-15 [9259214.001]
  • [Cites] Am J Obstet Gynecol. 1997 Aug;177(2):478-9 [9290479.001]
  • [Cites] Mol Hum Reprod. 1998 Jan;4(1):83-6 [9510016.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):316-22 [10398424.001]
  • [Cites] Adv Anat Pathol. 1999 Sep;6(5):237-46 [10472377.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):158-63 [10502446.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):742-5 [15581996.001]
  • [Cites] BMC Gastroenterol. 2005;5:33 [16223449.001]
  • [Cites] Fertil Steril. 2006 Feb;85(2):492-3 [16595233.001]
  • [Cites] Am J Obstet Gynecol. 2006 Oct;195(4):955-64 [16723104.001]
  • [Cites] Obstet Gynecol. 2006 Oct;108(4):930-7 [17012456.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] J Minim Invasive Gynecol. 2007 Mar-Apr;14(2):156-60 [17368249.001]
  • [Cites] J Minim Invasive Gynecol. 2007 Nov-Dec;14(6):770-5 [17980343.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):899-910 [18004397.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Arch Gynecol Obstet. 2008 Jul;278(1):93-5 [18193441.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1065-70 [17986239.001]
  • [Cites] Gynecol Obstet Invest. 2009;67(2):96-102 [18946223.001]
  • [Cites] Hum Genet. 2009 Apr;125(3):257-63 [19132395.001]
  • [Cites] Abdom Imaging. 2009 Mar-Apr;34(2):235-8 [18311496.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Oct;48(10):865-85 [19603527.001]
  • [Cites] Gynecol Obstet Invest. 2010;69(4):239-44 [20068330.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Mar;68(3):271-2 [10699204.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2000 May;7(2):227-32 [10806267.001]
  • [Cites] Environ Health Perspect. 2000 Oct;108 Suppl 5:821-7 [11035989.001]
  • [Cites] Clin Obstet Gynecol. 2001 Jun;44(2):335-49 [11344997.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1409-13 [11373202.001]
  • [Cites] BJOG. 2001 Jun;108(6):661-4 [11426907.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4554-7 [12183404.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):205-6 [12508249.001]
  • [Cites] Pathol Int. 2003 Mar;53(3):179-85 [12608900.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1351-8 [12649198.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1241-52 [12761039.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Sep;38(1):68-79 [12874787.001]
  • [Cites] Obstet Gynecol. 2003 Nov;102(5 Pt 2):1125-7 [14607029.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):17-22 [14695314.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):113-23 [14718211.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):183-90 [15334541.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 May 13;374(1):13-26 [141779.001]
  • [Cites] Am J Obstet Gynecol. 1980 Apr 15;136(8):992-6 [7369273.001]
  • (PMID = 20842731.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD060530-01A1; United States / NHGRI NIH HHS / HG / HG004221; United States / NICHD NIH HHS / HD / HD060530; United States / NICHD NIH HHS / HD / R01 HD060530-01A1; United States / NICHD NIH HHS / HD / R01 HD060530-02; United States / NICHD NIH HHS / HD / R01 HD060530; United States / NICHD NIH HHS / HD / HD060530-02; United States / NCI NIH HHS / CA / P30 CA006516; United States / NHGRI NIH HHS / HG / P41 HG004221
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232518; NLM/ PMC2955189
  •  go-up   go-down


90. Viggiano AA: Much improved upper limit for the rate constant for the reaction of O2+ with N2. J Phys Chem A; 2006 Oct 19;110(41):11599-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Much improved upper limit for the rate constant for the reaction of O2+ with N2.
  • Much improved upper limits for this reaction at the three temperatures are 2, 4, and 10x10(-21) cm3 s-1, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034151.001).
  • [ISSN] 1089-5639
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Meroni M, Battevi N, Vitelli N, Ricci MG, Petri A, Menoni O, Colombini D: [Epidemiological study of UL-WMSDs in 2022 VDU workers]. Med Lav; 2010 Jul-Aug;101(4):276-85
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological study of UL-WMSDs in 2022 VDU workers].
  • BACKGROUND: The literature dealing with the health effects of VDU work identified right from the beginning a group of MSDs, mainly affecting the cervicobrachial region, so that VDU work could be considered a risk factor due to biomechanical overload of the upper limbs, OBJECTIVES: The aim of the study was to assess the prevalence of symptoms and diseases of VDU workers.
  • METHODS: A cohort of 2022 workers (1125 males and 897 females) working at VDUs for a duration of time equal to or exceeding 20 hours per week, including insurance and bank employees (no desk activity), was submitted to clinical and functional assessment of the cervical spine and upper limbs following a structured protocol (case history, clinical and instrumental examinations), as used by occupational physicians, in order to identify "anamnestic cases" and diagnose upper limb biomechanical overload diseases.
  • RESULTS: The prevalence of subjects with UL-WMSDs was 1.9% for males and 5.8% for females, and basically similar to that found in non-exposed working populations.
  • CONCLUSIONS: In the sample studied no association was shown between VDU work and onset of upper limb diseases, which was confirmed even considering the different exposure variables.
  • Analysis of"anamnestic cases" made by comparison with non-exposed populations, confirmed the lack of association between upper limb diseases and VDU work.
  • [MeSH-major] Arm. Musculoskeletal Diseases / epidemiology. Occupational Diseases / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21090126.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


92. Beraneck M, McKee JL, Aleisa M, Cullen KE: Asymmetric recovery in cerebellar-deficient mice following unilateral labyrinthectomy. J Neurophysiol; 2008 Aug;100(2):945-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymmetric recovery in cerebellar-deficient mice following unilateral labyrinthectomy.
  • We found that during exploratory activity, normal mice produce head rotations largely consisting of frequencies < or =4 Hz and velocities and accelerations as large as 400 degrees/s and 5,000 degrees/s2, respectively.
  • After unilateral labyrinthectomy, VOR recovery followed a similar course for WT and Lc/+ groups during the first week: gain was reduced by 80% for ipsilesionally directed head rotations on day 1 and improved for both strains to values of approximately 0.4 by day 5.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurophysiol. 1984 Dec;52(6):1140-53 [6335171.001]
  • [Cites] Exp Brain Res. 1989;77(1):166-82 [2792260.001]
  • [Cites] Neurosci Lett. 1997 Aug 15;231(3):147-50 [9300643.001]
  • [Cites] Exp Brain Res. 1983;50(2-3):259-74 [6641859.001]
  • [Cites] Exp Brain Res. 1983;53(1):36-46 [6609085.001]
  • [Cites] Brain Res. 1984 Jun 8;302(2):245-56 [6610459.001]
  • [Cites] J Neurophysiol. 1988 Feb;59(2):370-93 [3258362.001]
  • [Cites] Brain Res. 1988 Mar 22;444(2):295-307 [3359297.001]
  • [Cites] Neuroscience. 1999;94(1):1-5 [10613489.001]
  • [Cites] J Physiol. 2000 Mar 1;523 Pt 2:413-24 [10699085.001]
  • [Cites] Curr Opin Neurol. 2000 Feb;13(1):27-30 [10719646.001]
  • [Cites] J Neurophysiol. 2000 May;83(5):2482-96 [10805650.001]
  • [Cites] J Neurosci. 2000 May 15;20(10):3687-94 [10804210.001]
  • [Cites] Prog Neurobiol. 2000 Oct;62(3):313-25 [10840152.001]
  • [Cites] Neuroreport. 2000 Jun 26;11(9):1921-7 [10884044.001]
  • [Cites] J Neurophysiol. 2000 Jul;84(1):581-4 [10899230.001]
  • [Cites] J Neurosci Methods. 2000 Jun 30;99(1-2):101-10 [10936649.001]
  • [Cites] Acta Otolaryngol. 2000 Oct;120(7):866-71 [11132722.001]
  • [Cites] Brain Res. 2001 Feb 2;890(2):296-305 [11164796.001]
  • [Cites] Prog Neurobiol. 2001 Apr;63(5):489-540 [11164620.001]
  • [Cites] Neuroreport. 2001 Mar 5;12(3):597-600 [11234771.001]
  • [Cites] Neurosci Res. 2001 Mar;39(3):299-311 [11248370.001]
  • [Cites] J Neurosci. 2001 Apr 15;21(8):2738-48 [11306626.001]
  • [Cites] Exp Brain Res. 2001 Apr;137(3-4):369-86 [11355383.001]
  • [Cites] J Neurophysiol. 2001 Jun;85(6):2643-6 [11387410.001]
  • [Cites] Brain Res. 2001 Jul 20;908(1):58-66 [11457431.001]
  • [Cites] J Neurophysiol. 2002 Feb;87(2):1159-64 [11826084.001]
  • [Cites] Eur J Neurosci. 2002 Jun;15(11):1719-27 [12081651.001]
  • [Cites] J Neurophysiol. 2002 Jul;88(1):13-28 [12091529.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1044-54 [12220209.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):921-33 [12372286.001]
  • [Cites] Neuroreport. 2002 Oct 28;13(15):1875-9 [12395083.001]
  • [Cites] Exp Brain Res. 2002 Dec;147(3):374-86 [12428145.001]
  • [Cites] J Physiol. 2002 Dec 15;545(Pt 3):903-11 [12482895.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;978:413-24 [12582070.001]
  • [Cites] J Neurophysiol. 2003 Jul;90(1):184-203 [12649317.001]
  • [Cites] Neuron. 2003 Oct 30;40(3):609-20 [14642283.001]
  • [Cites] Ann N Y Acad Sci. 2003 Oct;1004:50-60 [14662447.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Feb;261(2):82-6 [12851830.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2440-8 [15014119.001]
  • [Cites] Learn Mem. 2004 Mar-Apr;11(2):127-36 [15054127.001]
  • [Cites] Neuroscience. 2004;127(3):785-96 [15283975.001]
  • [Cites] J Neurophysiol. 2004 Sep;92(3):1668-84 [15140902.001]
  • [Cites] J Physiol. 2004 Sep 1;559(Pt 2):625-38 [15243133.001]
  • [Cites] Laryngoscope. 1969 Oct;79(10):1728-36 [5345406.001]
  • [Cites] Exp Brain Res. 1972 Apr 27;14(5):511-26 [5047283.001]
  • [Cites] Exp Brain Res. 1973;17(3):301-14 [4722119.001]
  • [Cites] Brain Res. 1974 Jan 4;65(1):170-4 [4810171.001]
  • [Cites] Brain Res. 1975 Jun 27;91(2):276-80 [1164674.001]
  • [Cites] J Neurophysiol. 1976 Sep;39(5):954-69 [1086347.001]
  • [Cites] J Comp Neurol. 1977 May 1;173(1):205-18 [845284.001]
  • [Cites] J Physiol. 1977 Mar;265(3):833-54 [300801.001]
  • [Cites] Brain Res. 1977 Oct 21;135(1):192-6 [912433.001]
  • [Cites] Exp Brain Res. 1982;45(1-2):233-42 [7056329.001]
  • [Cites] Brain Res. 1982 May 6;239(1):251-7 [7093679.001]
  • [Cites] J Neurophysiol. 1983 Jan;49(1):152-68 [6827292.001]
  • [Cites] Brain Res. 1983 Aug 22;273(1):175-8 [6616225.001]
  • [Cites] Prog Neurobiol. 1997 Feb;51(3):243-86 [9089790.001]
  • [Cites] Neurology. 1997 Apr;48(4):916-20 [9109877.001]
  • [Cites] Neuroreport. 1997 May 27;8(8):1891-5 [9223072.001]
  • [Cites] J Comp Neurol. 1997 Aug 11;384(4):580-96 [9259491.001]
  • [Cites] Neuroreport. 1997 Jul 28;8(11):2595-9 [9261834.001]
  • [Cites] Nature. 1997 Aug 21;388(6644):769-73 [9285588.001]
  • [Cites] Brain Res. 1988 Mar 22;444(2):308-19 [3359298.001]
  • [Cites] Brain Res. 1988 Apr 19;446(2):225-35 [2453257.001]
  • [Cites] Acta Otolaryngol. 1988 Mar-Apr;105(3-4):328-37 [3389119.001]
  • [Cites] Biol Cybern. 1988;60(2):111-9 [3228554.001]
  • [Cites] Brain Res Brain Res Rev. 1989 Apr-Jun;14(2):155-80 [2665890.001]
  • [Cites] Acta Otolaryngol. 1989 Jul-Aug;108(1-2):1-8 [2788346.001]
  • [Cites] Exp Brain Res. 1990;81(3):479-90 [2226683.001]
  • [Cites] Neuroreport. 1992 Oct;3(10):829-32 [1421082.001]
  • [Cites] Arch Ital Biol. 1993 Jan;131(1):71-4 [8481087.001]
  • [Cites] Exp Brain Res. 1993;94(1):16-32 [8335071.001]
  • [Cites] J Neurophysiol. 1993 Jul;70(1):117-27 [8395570.001]
  • [Cites] Exp Brain Res. 1993;97(2):263-73 [8150045.001]
  • [Cites] Cell. 1995 Apr 21;81(2):245-52 [7736576.001]
  • [Cites] Genes Funct. 1997 Jun;1(3):175-90 [9680293.001]
  • [Cites] J Neurophysiol. 1998 Sep;80(3):1151-66 [9744929.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Oct 30;61(1-2):170-8 [9795202.001]
  • [Cites] J Neurophysiol. 1998 Nov;80(5):2352-67 [9819248.001]
  • [Cites] Exp Brain Res. 1998 Dec;123(3):242-54 [9860262.001]
  • [Cites] Brain Res. 1999 Jan 30;817(1-2):246-55 [9889379.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;539:19-27 [10095856.001]
  • [Cites] Eur J Neurosci. 1999 May;11(5):1827-30 [10215935.001]
  • [Cites] Exp Brain Res. 1999 Apr;125(3):353-64 [10229026.001]
  • [Cites] J Physiol. 1999 Jul 1;518 ( Pt 1):151-8 [10373697.001]
  • [Cites] J Neurophysiol. 1999 Sep;82(3):1271-85 [10482746.001]
  • [Cites] Vision Res. 2004 Dec;44(28):3401-10 [15536008.001]
  • [Cites] Brain Res. 2005 Mar 21;1038(2):183-97 [15757634.001]
  • [Cites] Eur J Neurosci. 2005 Mar;21(5):1315-26 [15813941.001]
  • [Cites] Neuron. 2005 May 19;46(4):623-31 [15944130.001]
  • [Cites] Prog Neurobiol. 2005 Aug;76(6):349-92 [16263204.001]
  • [Cites] Mol Neurobiol. 2006 Feb;33(1):1-16 [16388107.001]
  • [Cites] J Assoc Res Otolaryngol. 2006 Jun;7(2):151-9 [16718609.001]
  • [Cites] Curr Opin Neurobiol. 2006 Aug;16(4):385-90 [16842990.001]
  • [Cites] J Neurophysiol. 2006 Sep;96(3):1187-95 [16723418.001]
  • [Cites] J Physiol. 2006 Sep 15;575(Pt 3):777-88 [16825307.001]
  • [Cites] Exp Brain Res. 2006 Nov;175(3):471-84 [16957885.001]
  • [Cites] Brain Res. 2007 Apr 6;1140:4-18 [16412991.001]
  • [Cites] J Comp Neurol. 2007 Oct 1;504(4):418-26 [17663432.001]
  • [Cites] J Neurophysiol. 2007 Sep;98(3):1549-65 [17625061.001]
  • [Cites] J Physiol. 2007 Sep 15;583(Pt 3):923-43 [17627998.001]
  • [Cites] Neurology. 2008 Feb 5;70(6):454-63 [18250290.001]
  • [Cites] J Vestib Res. 1995 Mar-Apr;5(2):67-107 [7743004.001]
  • [Cites] Prog Neurobiol. 1995 Jun;46(2-3):97-129 [7568917.001]
  • [Cites] J Neurophysiol. 1995 Nov;74(5):2087-99 [8592199.001]
  • [Cites] Neurosci Lett. 1995 Nov 17;200(2):109-12 [8614556.001]
  • [Cites] Neuroscience. 1996 Jan;70(2):515-46 [8848156.001]
  • [Cites] Neuroreport. 1995 Dec 29;7(1):189-92 [8742448.001]
  • [Cites] Neuron. 1996 Dec;17(6):1251-64 [8982171.001]
  • [Cites] Neuroscience. 1997 Jan;76(2):571-80 [9015339.001]
  • [Cites] Neurosci Lett. 1997 Feb 7;222(3):171-4 [9148242.001]
  • [ErratumIn] J Neurophysiol. 2008 Dec;100(6):3461
  • (PMID = 18509072.001).
  • [ISSN] 0022-3077
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2525728
  •  go-up   go-down


93. Abraham J, Abreu P, Aglietta M, Aguirre C, Allard D, Allekotte I, Allen J, Allison P, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anzalone A, Aramo C, Argirò S, Arisaka K, Armengaud E, Arneodo F, Arqueros F, Asch T, Asorey H, Assis P, Atulugama BS, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Barbosa AF, Barnhill D, Barroso SL, Bauleo P, Beatty JJ, Beau T, Becker BR, Becker KH, Bellido JA, BenZvi S, Berat C, Bergmann T, Bernardini P, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blasi P, Bleve C, Blümer H, Bohácová M, Bonifazi C, Bonino R, Boratav M, Brack J, Brogueira P, Brown WC, Buchholz P, Bueno A, Burton RE, Busca NG, Caballero-Mora KS, Cai B, Camin DV, Caramete L, Caruso R, Carvalho W, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chye J, Clark PD, Clay RW, Colombo E, Conceição R, Connolly B, Contreras F, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Daumiller K, Dawson BR, de Almeida RM, De Donato C, de Jong SJ, De La Vega G, de Mello Junior WJ, de Mello Neto JR, DeMitri I, de Souza V, del Peral L, Deligny O, Della Selva A, Delle Fratte C, Dembinski H, Di Giulio C, Diaz JC, Dobrigkeit C, D'Olivo JC, Dornic D, Dorofeev A, dos Anjos JC, Dova MT, D'Urso D, Dutan I, DuVernois MA, Engel R, Epele L, Erdmann M, Escobar CO, Etchegoyen A, Facal San Luis P, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferrer F, Ferry S, Fick B, Filevich A, Filipcic A, Fleck I, Fonte R, Fracchiolla CE, Fulgione W, García B, García Gámez D, Garcia-Pinto D, Garrido X, Geenen H, Gelmini G, Gemmeke H, Ghia PL, Giller M, Glass H, Gold MS, Golup G, Gomez Albarracin F, Gómez Berisso M, Gómez Herrero R, Gonçalves P, Gonçalves do Amaral M, Gonzalez D, Gonzalez JG, González M, Góra D, Gorgi A, Gouffon P, Grassi V, Grillo AF, Grunfeld C, Guardincerri Y, Guarino F, Guedes GP, Gutiérrez J, Hague JD, Hamilton JC, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hauschildt T, Healy MD, Hebbeker T, Hebrero G, Heck D, Hojvat C, Holmes VC, Homola P, Hörandel J, Horneffer A, Horvat M, Hrabovský M, Huege T, Hussain M, Iarlori M, Insolia A, Ionita F, Italiano A, Kaducak M, Kampert KH, Karova T, Kégl B, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Krieger A, Krömer O, Kuempel D, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lebrun D, Lebrun P, Lee J, Leigui de Oliveira MA, Letessier-Selvon A, Leuthold M, Lhenry-Yvon I, López R, Lopez Agüera A, Lozano Bahilo J, Luna García R, Maccarone MC, Macolino C, Maldera S, Mancarella G, Manceñido ME, Mandat D, Mantsch P, Mariazzi AG, Maris IC, Marquez Falcon HR, Martello D, Martínez J, Martínez Bravo O, Mathes HJ, Matthews J, Matthews JA, Matthiae G, Maurizio D, Mazur PO, McCauley T, McEwen M, McNeil RR, Medina MC, Medina-Tanco G, Meli A, Melo D, Menichetti E, Menschikov A, Meurer C, Meyhandan R, Micheletti MI, Miele G, Miller W, Mollerach S, Monasor M, Monnier Ragaigne D, Montanet F, Morales B, Morello C, Moreno JC, Morris C, Mostafá M, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Newman-Holmes C, Newton D, Nguyen Thi T, Nierstenhoefer N, Nitz D, Nosek D, Nozka L, Oehlschläger J, Ohnuki T, Olinto A, Olmos-Gilbaja VM, Ortiz M, Ortolani F, Ostapchenko S, Otero L, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Parente G, Parizot E, Parlati S, Pastor S, Patel M, Paul T, Pavlidou V, Payet K, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Petrera S, Petrinca P, Petrov Y, Pham Ngoc D, Pham Ngoc D, Pham Thi TN, Pichel A, Piegaia R, Pierog T, Pimenta M, Pinto T, Pirronello V, Pisanti O, Platino M, Pochon J, Privitera P, Prouza M, Quel EJ, Rautenberg J, Redondo A, Reucroft S, Revenu B, Rezende FA, Ridky J, Riggi S, Risse M, Rivière C, Rizi V, Roberts M, Robledo C, Rodriguez G, Rodríguez Frías D, Rodriguez Martino J, Rodriguez Rojo J, Rodriguez-Cabo I, Ros G, Rosado J, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos EM, Sarazin F, Sarkar S, Sato R, Scherini V, Schieler H, Schmidt A, Schmidt F, Schmidt T, Scholten O, Schovánek P, Schüssler F, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shellard RC, Sidelnik I, Siffert BB, Sigl G, Smetniansky De Grande N, Smiałkowski A, Smída R, Smith AG, Smith BE, Snow GR, Sokolsky P, Sommers P, Sorokin J, Spinka H, Squartini R, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Takahashi J, Tamashiro A, Tamburro A, Taşcău O, Tcaciuc R, Thomas D, Ticona R, Tiffenberg J, Timmermans C, Tkaczyk W, Todero Peixoto CJ, Tomé B, Tonachini A, Torres I, Torresi D, Travnicek P, Tripathi A, Tristram G, Tscherniakhovski D, Tueros M, Tunnicliffe V, Ulrich R, Unger M, Urban M, Valdés Galicia JF, Valiño I, Valore L, van den Berg AM, van Elewyck V, Vázquez RA, Veberic D, Veiga A, Velarde A, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wainberg O, Walker P, Warner D, Watson AA, Westerhoff S, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Wileman C, Winnick MG, Wu H, Wundheiler B, Yamamoto T, Younk P, Zas E, Zavrtanik D, Zavrtanik M, Zech A, Zepeda A, Ziolkowski M, Pierre Auger Collaboration: Upper limit on the diffuse flux of ultrahigh energy tau neutrinos from the Pierre Auger Observatory. Phys Rev Lett; 2008 May 30;100(21):211101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limit on the diffuse flux of ultrahigh energy tau neutrinos from the Pierre Auger Observatory.
  • The data collected between 1 January 2004 and 31 August 2007 are used to place an upper limit on the diffuse flux of nu(tau) at EeV energies.
  • Assuming an E(nu)(-2) differential energy spectrum the limit set at 90% C.L. is E(nu)(2)dN(nu)(tau)/dE(nu)<1.3 x 10(-7) GeV cm(-2) s(-1) sr(-1) in the energy range 2 x 10(17) eV< E(nu)< 2 x 10(19) eV.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518595.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Zhou X, Liu Z: A scalable, solution-phase processing route to graphene oxide and graphene ultralarge sheets. Chem Commun (Camb); 2010 Apr 21;46(15):2611-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scalable, solution-phase processing route to graphene oxide and graphene ultralarge sheets.
  • High yield production of graphene oxide and graphene sheets with an ultralarge size (up to approximately 200 microm) was realized using a modified solution-phase method.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449324.001).
  • [ISSN] 1364-548X
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Baggio L, Bignotto M, Bonaldi M, Cerdonio M, Conti L, De Rosa M, Falferi P, Fortini P, Inguscio M, Liguori N, Marin F, Mezzena R, Mion A, Ortolan A, Prodi GA, Poggi S, Salemi F, Soranzo G, Taffarello L, Vedovato G, Vinante A, Vitale S, Zendri JP, AURIGA Collaboration: Upper limits on gravitational-wave emission in association with the 27 Dec 2004 giant flare of SGR1806-20. Phys Rev Lett; 2005 Aug 19;95(8):081103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limits on gravitational-wave emission in association with the 27 Dec 2004 giant flare of SGR1806-20.
  • This allows us to set relevant upper limits, at a number of frequencies in the vicinities of 900 Hz, on the amplitude of the damped GW wave trains, which, according to current models, could have been emitted, due to the excitation of normal modes of the star associated with the peak in x-ray luminosity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Phys Rev Lett. 2005 Sep 23;95(13):139903
  • (PMID = 16196848.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Hong SM, Lee JH, Yeo SG, Cha CI, Park BR: Temporal Changes of the Calcium-binding Proteins in the Medial Vestibular Nucleus following Unilateral Labyrinthectomy in Rats. Korean J Physiol Pharmacol; 2008 Jun;12(3):95-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal Changes of the Calcium-binding Proteins in the Medial Vestibular Nucleus following Unilateral Labyrinthectomy in Rats.
  • This study examined temporal changes of three calcium-binding proteins (calretinin, calbindin and parvalbumin) in the medial vestibular nucleus (MVN) during vestibular compensation after unilateral labyrinthectomy (UL) in rats.
  • Rats underwent UL, and the changes in the expression of these proteins at 2, 6, 12, 24, 48, and 72 h were examined by immunofluorescence staining.
  • The expression levels of all three proteins increased immediately after UL and returned to the control level by 48 h.
  • However, the level of calretinin showed changes different from the other two proteins, being expressed at significantly higher level in the contralateral MVN than in the ipsilateral MVN 2 h after UL, whereas the other two proteins showed similar expression levels in both the ipsilateral and contralateral MVN.
  • These results suggest that the calcium binding proteins have some protective activity against the increased Ca(2+) levels in the MVN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Brain Res. 2005 Jul;164(1):78-91 [15662522.001]
  • [Cites] J Comp Neurol. 1991 Aug 1;310(1):21-44 [1939729.001]
  • [Cites] Pol J Pharmacol. 1999 Mar-Apr;51(2):173-8 [10425647.001]
  • [Cites] Neurosci Res. 1998 Sep;32(1):75-84 [9831254.001]
  • [Cites] Neuroscience. 1990;35(2):375-475 [2199841.001]
  • [Cites] Exp Brain Res. 1981;43(3-4):383-94 [7262231.001]
  • [Cites] Brain Res. 2004 Jun 18;1011(2):238-42 [15157810.001]
  • [Cites] Neurosci Lett. 2002 Feb 8;319(1):9-12 [11814641.001]
  • [Cites] Neurosci Lett. 2000 Apr 7;283(2):117-20 [10739889.001]
  • [Cites] J Comp Neurol. 2000 Jan 10;416(2):173-87 [10581464.001]
  • [Cites] Neurosci Res. 1998 Feb;30(2):155-68 [9579649.001]
  • [Cites] Neurosci Lett. 1997 Aug 15;231(3):147-50 [9300643.001]
  • [Cites] J Comp Neurol. 1997 Sep 22;386(2):317-27 [9295155.001]
  • [Cites] Neuroscience. 1997 Jan;76(2):571-80 [9015339.001]
  • [Cites] J Comp Neurol. 1997 Feb 3;378(1):1-15 [9120049.001]
  • [Cites] Brain Res. 1996 Nov 18;740(1-2):208-14 [8973816.001]
  • [Cites] Brain Res Mol Brain Res. 1995 Jan;28(1):1-11 [7707861.001]
  • [Cites] Science. 1995 Apr 14;268(5208):239-47 [7716515.001]
  • [Cites] J Comp Neurol. 1995 Apr 17;354(4):564-82 [7608338.001]
  • [Cites] J Physiol. 1993 Dec;472:341-57 [8145149.001]
  • [Cites] J Comp Neurol. 1999 Aug 30;411(3):413-30 [10413776.001]
  • (PMID = 20157401.001).
  • [ISSN] 2093-3827
  • [Journal-full-title] The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
  • [ISO-abbreviation] Korean J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2817552
  • [Keywords] NOTNLM ; Calcium-binding proteins / Medial vestibular nuclei / Vestibular compensation
  •  go-up   go-down


97. Risse M, Homola P, Engel R, Góra D, Heck D, Pekala J, Wilczyńska B, Wilczyński H: Upper limit on the photon fraction in highest-energy cosmic rays from AGASA data. Phys Rev Lett; 2005 Oct 21;95(17):171102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper limit on the photon fraction in highest-energy cosmic rays from AGASA data.
  • A new method to derive an upper limit on photon primaries from small data sets of air showers is developed which accounts for shower properties varying with the primary energy and arrival direction.
  • Applying this method to the highest-energy showers recorded by the AGASA experiment, an upper limit on the photon fraction of 51% (67%) at a confidence level of 90% (95%) for primary energies above 1.25 x 10(20) eV is set.
  • This new limit on the photon fraction above the Greisen-Zatsepin-Kuzmin cutoff energy constrains the -burst model of the origin of highest-energy cosmic rays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383814.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Makan J, Sharma S, Firoozi S, Whyte G, Jackson PG, McKenna WJ: Physiological upper limits of ventricular cavity size in highly trained adolescent athletes. Heart; 2005 Apr;91(4):495-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physiological upper limits of ventricular cavity size in highly trained adolescent athletes.
  • OBJECTIVES: To define physiological upper limits of left ventricular (LV) cavity size in trained adolescent athletes.
  • LV cavity size correlated with age, sex, heart rate, and body surface area.
  • In highly trained adolescent athletes with an LV cavity size > 60 mm and any impairment of systolic or diastolic function, the diagnosis of dilated cardiomyopathy should be considered.
  • [MeSH-minor] Adolescent. Aging / pathology. Cardiomyopathy, Dilated / diagnosis. Cardiomyopathy, Dilated / pathology. Cardiomyopathy, Dilated / physiopathology. Cross-Sectional Studies. Echocardiography. Female. Heart Ventricles / anatomy & histology. Heart Ventricles / growth & development. Heart Ventricles / ultrasonography. Humans. Male. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol. 1973 Aug;35(2):288-93 [4737365.001]
  • [Cites] Circulation. 2000 Jan 25;101(3):336-44 [10645932.001]
  • [Cites] Circulation. 1978 Feb;57(2):237-44 [618610.001]
  • [Cites] Mayo Clin Proc. 1978 May;53(5):271-303 [642598.001]
  • [Cites] Am J Cardiol. 1978 Jul;42(1):52-6 [677037.001]
  • [Cites] Circulation. 1978 Dec;58(6):1072-83 [709763.001]
  • [Cites] Circulation. 1980 Apr;61(4):832-40 [6444559.001]
  • [Cites] Br Heart J. 1981 Aug;46(2):190-5 [7272130.001]
  • [Cites] Eur Heart J. 1982 Apr;3 Suppl A:193-8 [6210546.001]
  • [Cites] Circulation. 1983 Apr;67(4):896-901 [6825246.001]
  • [Cites] Br Heart J. 1983 Dec;50(6):534-9 [6651996.001]
  • [Cites] Circulation. 1985 Jan;71(1):39-44 [4038369.001]
  • [Cites] N Engl J Med. 1985 Jul 4;313(1):24-32 [3158817.001]
  • [Cites] J Am Coll Cardiol. 1985 Jul;6(1):1-18 [4040139.001]
  • [Cites] J Am Coll Cardiol. 1986 Jan;7(1):190-203 [2934463.001]
  • [Cites] Hypertension. 1987 Feb;9(2 Pt 2):II19-26 [2948914.001]
  • [Cites] Pediatrics. 1987 May;79(5):800-4 [2952938.001]
  • [Cites] Ann Intern Med. 1988 Jul 15;109(2):122-6 [3289430.001]
  • [Cites] Am J Cardiol. 1994 Oct 15;74(8):802-6 [7942554.001]
  • [Cites] JAMA. 1996 Jul 17;276(3):199-204 [8667563.001]
  • [Cites] Ann Intern Med. 1999 Jan 5;130(1):23-31 [9890846.001]
  • [Cites] Circulation. 1977 Jan;55(1):142-5 [830202.001]
  • (PMID = 15772210.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1768829
  •  go-up   go-down


99. Basavarajaiah S, Wilson M, Naghavi R, Whyte G, Turner M, Sharma S: Physiological upper limits of left ventricular dimensions in highly trained junior tennis players. Br J Sports Med; 2007 Nov;41(11):784-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physiological upper limits of left ventricular dimensions in highly trained junior tennis players.
  • BACKGROUND: The differentiation between physiological cardiac enlargement and cardiomyopathy is crucial, considering that most young non-traumatic deaths in sport are due to cardiomyopathy.
  • The aim of this study was to define the upper limits of left ventricular dimensions in a large cohort of national adolescent tennis players.
  • METHODS: Between 1996 and 2003, 259 adolescent tennis players (152 males), mean (SD) age 14.8 (1.4) years (range 13-19) and 86 healthy age, gender and body surface matched sedentary controls underwent 12-lead ECG and 2D-transthoracic echocardiography.
  • [MeSH-major] Heart Ventricles / anatomy & histology. Hypertrophy, Left Ventricular / diagnosis. Tennis / physiology. Ventricular Function, Left / physiology
  • [MeSH-minor] Adolescent. Adult. Body Weights and Measures. Case-Control Studies. Cohort Studies. Diagnosis, Differential. Echocardiography. Electrocardiography. Female. Heart Rate / physiology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Prat. 2001 Jun 30;51(12 Suppl):S31-5 [11505865.001]
  • [Cites] J Am Coll Cardiol. 2002 Oct 16;40(8):1431-6 [12392833.001]
  • [Cites] N Engl J Med. 2003 Sep 11;349(11):1064-75 [12968091.001]
  • [Cites] Circulation. 1978 Dec;58(6):1072-83 [709763.001]
  • [Cites] Circulation. 1980 Aug;62(2):212-7 [7397962.001]
  • [Cites] J Am Coll Cardiol. 1986 Jan;7(1):204-14 [3510233.001]
  • [Cites] Br J Sports Med. 2006 May;40(5):378 [16632563.001]
  • [Cites] N Engl J Med. 1991 Jan 31;324(5):295-301 [1824720.001]
  • [Cites] Circulation. 1995 Mar 1;91(5):1596-601 [7867202.001]
  • [Cites] JAMA. 1996 Jul 17;276(3):199-204 [8667563.001]
  • [Cites] Ann Intern Med. 1999 Jan 5;130(1):23-31 [9890846.001]
  • [Cites] Heart. 2005 Apr;91(4):495-9 [15772210.001]
  • [Cites] Clin Sports Med. 1988 Apr;7(2):245-52 [2455607.001]
  • (PMID = 17957014.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2465269
  •  go-up   go-down


100. Mazeh N, Roth BJ: A mechanism for the upper limit of vulnerability. Heart Rhythm; 2009 Mar;6(3):361-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mechanism for the upper limit of vulnerability.
  • BACKGROUND: The strongest shock that induces reentry in the heart is the upper limit of vulnerability (ULV).
  • OBJECTIVE: The goal of this study was to examine the mechanism of the upper limit of vulnerability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circ Res. 1999 Oct 15;85(8):742-52 [10576949.001]
  • [Cites] Circ Res. 1999 Nov 26;85(11):1056-66 [10571537.001]
  • [Cites] IEEE Trans Biomed Eng. 2000 Jun;47(6):820-1 [10833857.001]
  • [Cites] J Cardiovasc Electrophysiol. 2000 Jul;11(7):785-96 [10921796.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1055-70 [10993768.001]
  • [Cites] J Cardiovasc Electrophysiol. 2000 Sep;11(9):998-1007 [11021470.001]
  • [Cites] J Electrocardiol. 2003;36 Suppl:51-6 [14716592.001]
  • [Cites] Arch Mal Coeur Vaiss. 1967 Apr;60(4):527-44 [4964651.001]
  • [Cites] J Physiol. 1977 Jun;268(1):177-210 [874889.001]
  • [Cites] Circulation. 1986 May;73(5):1022-8 [3698224.001]
  • [Cites] Med Biol Eng Comput. 1986 Mar;24(2):130-6 [3713273.001]
  • [Cites] IEEE Trans Biomed Eng. 1987 Jul;34(7):555-60 [3610207.001]
  • [Cites] Am J Physiol. 1988 Oct;255(4 Pt 2):H891-901 [3177678.001]
  • [Cites] Circ Res. 1991 Jun;68(6):1501-26 [1709839.001]
  • [Cites] Circulation. 1991 Aug;84(2):913-9 [1860233.001]
  • [Cites] Circ Res. 1992 Apr;70(4):707-15 [1551197.001]
  • [Cites] Crit Rev Biomed Eng. 1993;21(1):1-77 [8365198.001]
  • [Cites] IEEE Trans Biomed Eng. 1995 Dec;42(12):1174-84 [8550059.001]
  • [Cites] Biophys J. 1995 Dec;69(6):2195-210 [8599628.001]
  • [Cites] J Cardiovasc Electrophysiol. 1997 Jul;8(7):768-78 [9255684.001]
  • [Cites] J Cardiovasc Electrophysiol. 1997 Sep;8(9):1031-45 [9300301.001]
  • [Cites] Ann Biomed Eng. 1997 Nov-Dec;25(6):949-63 [9395041.001]
  • [Cites] Circ Res. 1998 May 4;82(8):918-25 [9576111.001]
  • [Cites] J Cardiovasc Electrophysiol. 1998 Apr;9(4):384-94 [9581954.001]
  • [Cites] Heart Rhythm. 2004 Dec;1(6):695-703 [15851241.001]
  • [Cites] Circ Res. 2005 Jul 22;97(2):168-75 [15976315.001]
  • [Cites] J Cardiovasc Electrophysiol. 2005 Jul;16(7):748-52 [16050833.001]
  • [Cites] Pacing Clin Electrophysiol. 2006 May;29(5):496-501 [16689845.001]
  • [CommentIn] Heart Rhythm. 2009 Mar;6(3):368-9 [19251213.001]
  • (PMID = 19251212.001).
  • [ISSN] 1556-3871
  • [Journal-full-title] Heart rhythm
  • [ISO-abbreviation] Heart Rhythm
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL057207; United States / NHLBI NIH HHS / HL / R01 HL057207-09; United States / NHLBI NIH HHS / HL / R01HL57207
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS100347; NLM/ PMC2672308
  •  go-up   go-down






Advertisement